1
|
van Velthoven R, Diamand R, Mozer P, Barry de Longchamp N. Letter to the Editor on "Comparison in Detection Rate of Clinically Significant Prostate Cancer Between Microultrasound-guided Prostate Biopsy (ExactVu) and Multiparametric Resonance Imaging-guided Prostate Biopsy (Koelis System)". Urology 2024:S0090-4295(24)00346-7. [PMID: 38729267 DOI: 10.1016/j.urology.2024.04.050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2024] [Revised: 04/17/2024] [Accepted: 04/30/2024] [Indexed: 05/12/2024]
Affiliation(s)
- R van Velthoven
- Chairman Emeritus, Urology Dpt, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium.
| | - R Diamand
- Department of Urology, Jules Bordet Institute, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium
| | - P Mozer
- Service d'Urologie. Groupe Hospitalier Pitié-Salpétrière. Paris. France
| | | |
Collapse
|
2
|
Lambert E, Chartier-Kastler E, Vaessen C, Beaugerie A, Cotte J, Rouprêt M, Mozer P, Parra J, Seisen T, Lenfant L. Reply to Carmen Gravina, Matteo Romagnoli, Antonio Nacchia, et al.'s Letter to the Editor re: Edward Lambert, Emmanuel Chartier-Kastler, Christophe Vaessen, et al. Robot-assisted Periprostatic Artificial Urinary Sphincter Implantation in Men with Neurogenic Stress Urinary Incontinence: Description of the Surgical Technique and Comparison of Long-term Functional Outcomes with the Open Approach. Eur Urol. 2024;85:139-145. Eur Urol 2024; 85:e140-e141. [PMID: 38267281 DOI: 10.1016/j.eururo.2023.12.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2023] [Accepted: 12/22/2023] [Indexed: 01/26/2024]
Affiliation(s)
- Edward Lambert
- Department of Urology, University Hospital Pitié-Salpêtrière, Paris, France; Department of Urology, Onze-Lieve-Vrouw Hospital, Aalst, Belgium.
| | | | - Christophe Vaessen
- Department of Urology, University Hospital Pitié-Salpêtrière, Paris, France
| | - Aurélien Beaugerie
- Department of Urology, University Hospital Pitié-Salpêtrière, Paris, France
| | - Juliette Cotte
- Department of Urology, University Hospital Pitié-Salpêtrière, Paris, France
| | - Morgan Rouprêt
- Department of Urology, University Hospital Pitié-Salpêtrière, Paris, France
| | - Pierre Mozer
- Department of Urology, University Hospital Pitié-Salpêtrière, Paris, France
| | - Jérôme Parra
- Department of Urology, University Hospital Pitié-Salpêtrière, Paris, France
| | - Thomas Seisen
- Department of Urology, University Hospital Pitié-Salpêtrière, Paris, France
| | - Louis Lenfant
- Department of Urology, University Hospital Pitié-Salpêtrière, Paris, France
| |
Collapse
|
3
|
Couchoux T, Jaouen T, Melodelima-Gonindard C, Baseilhac P, Branchu A, Arfi N, Aziza R, Barry Delongchamps N, Bladou F, Bratan F, Brunelle S, Colin P, Correas JM, Cornud F, Descotes JL, Eschwege P, Fiard G, Guillaume B, Grange R, Grenier N, Lang H, Lefèvre F, Malavaud B, Marcelin C, Moldovan PC, Mottet N, Mozer P, Potiron E, Portalez D, Puech P, Renard-Penna R, Roumiguié M, Roy C, Timsit MO, Tricard T, Villers A, Walz J, Debeer S, Mansuy A, Mège-Lechevallier F, Decaussin-Petrucci M, Badet L, Colombel M, Ruffion A, Crouzet S, Rabilloud M, Souchon R, Rouvière O. Performance of a Region of Interest-based Algorithm in Diagnosing International Society of Urological Pathology Grade Group ≥2 Prostate Cancer on the MRI-FIRST Database-CAD-FIRST Study. Eur Urol Oncol 2024:S2588-9311(24)00056-7. [PMID: 38493072 DOI: 10.1016/j.euo.2024.03.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2024] [Accepted: 03/01/2024] [Indexed: 03/18/2024]
Abstract
BACKGROUND AND OBJECTIVE Prostate multiparametric magnetic resonance imaging (MRI) shows high sensitivity for International Society of Urological Pathology grade group (GG) ≥2 cancers. Many artificial intelligence algorithms have shown promising results in diagnosing clinically significant prostate cancer on MRI. To assess a region-of-interest-based machine-learning algorithm aimed at characterising GG ≥2 prostate cancer on multiparametric MRI. METHODS The lesions targeted at biopsy in the MRI-FIRST dataset were retrospectively delineated and assessed using a previously developed algorithm. The Prostate Imaging-Reporting and Data System version 2 (PI-RADSv2) score assigned prospectively before biopsy and the algorithm score calculated retrospectively in the regions of interest were compared for diagnosing GG ≥2 cancer, using the areas under the curve (AUCs), and sensitivities and specificities calculated with predefined thresholds (PIRADSv2 scores ≥3 and ≥4; algorithm scores yielding 90% sensitivity in the training database). Ten predefined biopsy strategies were assessed retrospectively. KEY FINDINGS AND LIMITATIONS After excluding 19 patients, we analysed 232 patients imaged on 16 different scanners; 85 had GG ≥2 cancer at biopsy. At patient level, AUCs of the algorithm and PI-RADSv2 were 77% (95% confidence interval [CI]: 70-82) and 80% (CI: 74-85; p = 0.36), respectively. The algorithm's sensitivity and specificity were 86% (CI: 76-93) and 65% (CI: 54-73), respectively. PI-RADSv2 sensitivities and specificities were 95% (CI: 89-100) and 38% (CI: 26-47), and 89% (CI: 79-96) and 47% (CI: 35-57) for thresholds of ≥3 and ≥4, respectively. Using the PI-RADSv2 score to trigger a biopsy would have avoided 26-34% of biopsies while missing 5-11% of GG ≥2 cancers. Combining prostate-specific antigen density, the PI-RADSv2 and algorithm's scores would have avoided 44-47% of biopsies while missing 6-9% of GG ≥2 cancers. Limitations include the retrospective nature of the study and a lack of PI-RADS version 2.1 assessment. CONCLUSIONS AND CLINICAL IMPLICATIONS The algorithm provided robust results in the multicentre multiscanner MRI-FIRST database and could help select patients for biopsy. PATIENT SUMMARY An artificial intelligence-based algorithm aimed at diagnosing aggressive cancers on prostate magnetic resonance imaging showed results similar to expert human assessment in a prospectively acquired multicentre test database.
Collapse
Affiliation(s)
- Thibaut Couchoux
- Department of Urinary and Vascular Imaging, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France
| | | | | | - Pierre Baseilhac
- Department of Urinary and Vascular Imaging, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France
| | - Arthur Branchu
- Department of Urinary and Vascular Imaging, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France
| | - Nicolas Arfi
- Department of Urology, Hôpital Saint Joseph Saint Luc, Lyon, France
| | - Richard Aziza
- Department of Radiology, Institut Universitaire du Cancer de Toulouse, Toulouse, France
| | | | - Franck Bladou
- Department of Urology, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France
| | - Flavie Bratan
- Department of Diagnostic and Interventional Imaging, Hôpital Saint Joseph Saint Luc, Lyon, France
| | - Serge Brunelle
- Department of Radiology and Medical Imaging, Institut Paoli-Calmettes Cancer Center, Marseille, France
| | - Pierre Colin
- Department of Urology, Hôpital privé La Louvrière, Lille, France
| | - Jean-Michel Correas
- Department of Radiology, Hôpital Necker, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - François Cornud
- Department of Radiology, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Jean-Luc Descotes
- Université Grenoble Alpes, Grenoble, France; Department of Urology, Centre Hospitalier Universitaire de Grenoble, Grenoble, France
| | - Pascal Eschwege
- Department of Urology, Centre Hospitalier Régional et Universitaire de Nancy, Vandoeuvre, France
| | - Gaelle Fiard
- Université Grenoble Alpes, Grenoble, France; Department of Urology, Centre Hospitalier Universitaire de Grenoble, Grenoble, France
| | - Bénédicte Guillaume
- Department of Radiology, Centre Hospitalier Universitaire de Grenoble, Université Grenoble Apes, Grenoble, France
| | - Rémi Grange
- Department of Radiology, University Hospital of Saint-Etienne, Saint-Priest-en-Jarez, France
| | - Nicolas Grenier
- Department of Radiology, Centre Hospitalier Universitaire de Bordeaux, Hôpital Pellegrin, Bordeaux, France
| | - Hervé Lang
- Department of Urology, Centre Hospitalier Universitaire de Strasbourg, Nouvel Hôpital Civil, Strasbourg, France
| | - Frédéric Lefèvre
- Department of Radiology, Centre Hospitalier Régional et Universitaire de Nancy, Vandoeuvre, France
| | - Bernard Malavaud
- Department of Urology, Institut Universitaire du Cancer de Toulouse, Toulouse, France
| | - Clément Marcelin
- Department of Radiology, Centre Hospitalier Universitaire de Bordeaux, Hôpital Pellegrin, Bordeaux, France
| | - Paul C Moldovan
- Department of Urinary and Vascular Imaging, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France
| | - Nicolas Mottet
- Department of Urology, University Hospital of Saint-Etienne, Saint-Priest-en-Jarez, France
| | - Pierre Mozer
- Department of Urology, Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Eric Potiron
- Clinique Urologique de Nantes, Saint-Herblain, France
| | - Daniel Portalez
- Department of Radiology, Institut Universitaire du Cancer de Toulouse, Toulouse, France
| | - Philippe Puech
- Department of Radiology, Centre Hospitalier Régional et Universitaire de Lille, Lille, France
| | - Raphaele Renard-Penna
- Department of Radiology, Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Paris, France; GRC no 5, ONCOTYPE-URO, Sorbonne Universités, Paris, France
| | - Matthieu Roumiguié
- Department of Urology, Toulouse-Rangueil University Hospital, Toulouse France
| | - Catherine Roy
- Department of Radiology B, Centre Hospitalier Universitaire de Strasbourg, Nouvel Hôpital Civil, Strasbourg, France
| | - Marc-Olivier Timsit
- Department of Urology, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Thibault Tricard
- Department of Urology, Centre Hospitalier Universitaire de Strasbourg, Nouvel Hôpital Civil, Strasbourg, France
| | - Arnauld Villers
- Department of Urology, Univ. Lille, CHU Lille, Lille, France
| | - Jochen Walz
- Department of Urology, Institut Paoli-Calmettes Cancer Center, Marseille, France
| | - Sabine Debeer
- Department of Urinary and Vascular Imaging, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France
| | - Adeline Mansuy
- Department of Urinary and Vascular Imaging, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France
| | | | | | - Lionel Badet
- Department of Urology, University Hospital of Saint-Etienne, Saint-Priest-en-Jarez, France; Department of Urology, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France; Université Lyon 1, Université de Lyon, Lyon, France
| | - Marc Colombel
- Department of Urology, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France; Université Lyon 1, Université de Lyon, Lyon, France
| | - Alain Ruffion
- Université Lyon 1, Université de Lyon, Lyon, France; Department of Urology, Centre Hospitalier Lyon Sud, Hospices Cibvils de Lyon, Pierre-Bénite, France
| | - Sébastien Crouzet
- LabTau, INSERM Unit 1032, Lyon, France; Department of Urology, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France; Université Lyon 1, Université de Lyon, Lyon, France
| | - Muriel Rabilloud
- Université Lyon 1, Université de Lyon, Lyon, France; Pôle Santé Publique, Service de Biostatistique et Bioinformatique, Hospices Civils de Lyon, Lyon, France; CNRS, UMR 5558, Laboratoire de Biométrie et Biologie Évolutive, Équipe Biostatistique-Santé, Villeurbanne, France
| | | | - Olivier Rouvière
- Department of Urinary and Vascular Imaging, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France; LabTau, INSERM Unit 1032, Lyon, France; Université Lyon 1, Université de Lyon, Lyon, France.
| |
Collapse
|
4
|
Lambert E, Chartier-Kastler E, Vaessen C, Beaugerie A, Cotte J, Roupret M, Mozer P, Parra J, Seisen T, Lenfant L. Robot-assisted Periprostatic Artificial Urinary Sphincter Implantation in Men with Neurogenic Stress Urinary Incontinence: Description of the Surgical Technique and Comparison of Long-term Functional Outcomes with the Open Approach. Eur Urol 2024; 85:139-145. [PMID: 37914580 DOI: 10.1016/j.eururo.2023.09.025] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2023] [Revised: 09/02/2023] [Accepted: 09/28/2023] [Indexed: 11/03/2023]
Abstract
BACKGROUND Periprostatic artificial urinary sphincter implantation (pAUSi) is a rare yet relevant indication for male neurogenic stress urinary incontinence (SUI). OBJECTIVE To describe the surgical technique of robot-assisted pAUSi (RApAUSi) and compare the long-term functional results with the open pAUSi (OpAUSi). DESIGN, SETTING, AND PARTICIPANTS Data of 65 consecutive men with neurogenic SUI undergoing pAUSi between 2000 and 2022 in a tertiary centre were collected retrospectively. SURGICAL PROCEDURE Thirty-three patients underwent OpAUSi and 32 underwent RApAUSi. OpAUSi cases were performed by a single surgeon, experienced in functional urology and prosthetic surgery. RApAUSi cases were performed by the same surgeon together with a second surgeon, experienced in robotic surgery. MEASUREMENTS Outcome measures were achievement of complete urinary continence, intra- and postoperative complications, and surgical revision-free survival (SRFS). RESULTS AND LIMITATIONS RApAUSi showed superior results to OpAUSi in terms of median (interquartile range) operative time (RApAUSi: 170 [150-210] min vs OpAUSi: 245 [228-300] min; p < 0.001), estimated blood loss (RApAUSi: 20 [0-50] ml vs OpAUSi: 500 [350-700] ml; p < 0.001), and median length of hospital stay (LOS; RApAUSi: 5 [4-6] d vs OpAUSi: 11 [10-14] d; p < 0.001). Clavien-Dindo grade ≥3a complications occurred more frequently after OpAUSi (RApAUSi: 1/32 [3%] vs OpAUSi: 10/33 [30%]; p = 0.014). Achievement of complete urinary continence (zero pads) was comparable between the groups (RApAUSi: 24/32 [75%] vs OpAUSi: 24/33 [73%]; p = 0.500). The median follow-up periods were 118 (50-183) and 56 (25-84) mo for OpAUSi and RApAUSi, respectively (p < 0.001). A tendency towards longer SRFS was observed in the RApAUSi group (p = 0.076). The main study limitation was its retrospective nature. CONCLUSIONS RApAUSi is an efficient alternative to OpAUSi, resulting in shorter operative times, less blood loss, fewer severe complications, and a shorter LOS with similar functional results and need for revision surgery. PATIENT SUMMARY Compared with open periprostatic artificial urinary sphincter implantation (pAUSi), robot-assisted pAUSi leads to faster recovery and similar functional results, with fewer postoperative complications.
Collapse
Affiliation(s)
- Edward Lambert
- Department of Urology, University Hospital Pitié-Salpêtrière, Paris, France; J-ERUS/YAU Academic Urologists Working Group on Robot-Assisted Surgery, Paris, France.
| | - Emmanuel Chartier-Kastler
- Department of Urology, University Hospital Pitié-Salpêtrière, Paris, France; Faculty of Medicine Sorbonne University, Paris, France
| | - Christophe Vaessen
- Department of Urology, University Hospital Pitié-Salpêtrière, Paris, France
| | - Aurélien Beaugerie
- Department of Urology, University Hospital Pitié-Salpêtrière, Paris, France; Faculty of Medicine Sorbonne University, Paris, France
| | - Juliette Cotte
- Department of Urology, University Hospital Pitié-Salpêtrière, Paris, France; Faculty of Medicine Sorbonne University, Paris, France
| | - Morgan Roupret
- Department of Urology, University Hospital Pitié-Salpêtrière, Paris, France; Faculty of Medicine Sorbonne University, Paris, France
| | - Pierre Mozer
- Department of Urology, University Hospital Pitié-Salpêtrière, Paris, France; Faculty of Medicine Sorbonne University, Paris, France
| | - Jérôme Parra
- Department of Urology, University Hospital Pitié-Salpêtrière, Paris, France
| | - Thomas Seisen
- Department of Urology, University Hospital Pitié-Salpêtrière, Paris, France; Faculty of Medicine Sorbonne University, Paris, France
| | - Louis Lenfant
- Department of Urology, University Hospital Pitié-Salpêtrière, Paris, France; Faculty of Medicine Sorbonne University, Paris, France
| |
Collapse
|
5
|
Grobet-Jeandin E, Lenfant L, Pinar U, Parra J, Mozer P, Renard-Penna R, Thibault C, Rouprêt M, Seisen T. Management of patients with muscle-invasive bladder cancer with clinical evidence of pelvic lymph node metastases. Nat Rev Urol 2024:10.1038/s41585-023-00842-y. [PMID: 38297079 DOI: 10.1038/s41585-023-00842-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/01/2023] [Indexed: 02/02/2024]
Abstract
Identification of clinically positive pelvic lymph node metastases (cN+) in patients with muscle-invasive bladder cancer is currently challenging, as the diagnostic accuracy of available imaging modalities is limited. Conventional CT is still considered the gold-standard approach to diagnose lymph node metastases in these patients. The development of innovative diagnostic methods including radiomics, artificial intelligence-based models and molecular biomarkers might offer new perspectives for the diagnosis of cN+ disease. With regard to the treatment of these patients, multimodal strategies are likely to provide the best oncological outcomes, especially using induction chemotherapy followed by radical cystectomy and pelvic lymph node dissection in responders to chemotherapy. Additionally, the use of adjuvant nivolumab has been shown to decrease the risk of recurrence in patients who still harbour ypT2-T4a and/or ypN+ disease after surgery. Alternatively, the use of avelumab maintenance therapy can be offered to patients with unresectable cN+ tumours who have at least stable disease after induction chemotherapy alone. Lastly, patients with cN+ tumours who are not responding to induction chemotherapy are potential candidates for receiving second-line treatment with pembrolizumab.
Collapse
Affiliation(s)
- Elisabeth Grobet-Jeandin
- Sorbonne University, GRC 5, Predictive Onco-Urology, APHP, Pitié-Salpêtrière Hospital, Urology, 75013, Paris, France
- Division of Urology, Geneva University Hospitals, Geneva, Switzerland
| | - Louis Lenfant
- Sorbonne University, GRC 5, Predictive Onco-Urology, APHP, Pitié-Salpêtrière Hospital, Urology, 75013, Paris, France
| | - Ugo Pinar
- Sorbonne University, GRC 5, Predictive Onco-Urology, APHP, Pitié-Salpêtrière Hospital, Urology, 75013, Paris, France
| | - Jérôme Parra
- Sorbonne University, GRC 5, Predictive Onco-Urology, APHP, Pitié-Salpêtrière Hospital, Urology, 75013, Paris, France
| | - Pierre Mozer
- Sorbonne University, GRC 5, Predictive Onco-Urology, APHP, Pitié-Salpêtrière Hospital, Urology, 75013, Paris, France
| | - Raphaele Renard-Penna
- Sorbonne University, GRC 5, Predictive Onco-Urology, APHP, Pitié-Salpêtrière Hospital, Radiology, 75013, Paris, France
| | - Constance Thibault
- Department of medical oncology, Hôpital Européen Georges Pompidou, Institut du Cancer Paris CARPEM, AP-HP centre, Paris, France
| | - Morgan Rouprêt
- Sorbonne University, GRC 5, Predictive Onco-Urology, APHP, Pitié-Salpêtrière Hospital, Urology, 75013, Paris, France
| | - Thomas Seisen
- Sorbonne University, GRC 5, Predictive Onco-Urology, APHP, Pitié-Salpêtrière Hospital, Urology, 75013, Paris, France.
| |
Collapse
|
6
|
Gabriel PE, Pinar U, Lenfant L, Parra J, Vaessen C, Mozer P, Chartier-Kastler E, Rouprêt M, Seisen T. Perioperative, renal function and oncological outcomes of robot-assisted radical nephroureterectomy for patients with upper tract urothelial carcinoma. World J Urol 2023; 41:3001-3007. [PMID: 37676283 DOI: 10.1007/s00345-023-04590-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2023] [Accepted: 08/20/2023] [Indexed: 09/08/2023] Open
Abstract
PURPOSE To report perioperative, renal function and oncological outcomes of robot-assisted radical nephroureterectomy (RNU) for patients with upper tract urothelial carcinoma (UTUC). METHODS This was a retrospective single-arm monocentric study including all consecutive UTUC patients treated with robot-assisted RNU at our institution between 2014 and 2022. Descriptive statistics with median and interquartile range (IQR) for continuous variables and numbers with frequencies for categorical variables were used to report perioperative and renal function outcomes while Kaplan-Meier curves were computed to present extravesical and intravesical recurrence-free survival(RFS) as well as cancer-specific (CSS) and overall survival (OS) with the corresponding 95% confidence intervals(CIs). RESULTS Overall, 70 patients with a median age of 69.6 [63.3-74.9] years were included in our study. With regards to perioperative outcomes, the median operative time was 157 [130-182] min with a median blood loss of 200 [100-300] cc. Intraoperative complications occurred in 4 (5.7%) patients but no conversion to open or laparoscopic surgery was required. Postoperative complications occurred in 9 (12.9%) patients, including 5 (7.1%) with grade ≥ 3 complications according to the Clavien-Dindo classification. The median length of stay was 4 [3-6] days. With regards to renal function outcomes, the median postoperative loss in estimated glomerular filtration rate at discharge was 16 [10.25-26] mL/min/1.73 m2. With regards to oncological outcomes, the 3-year extravesical and intravesical RFS, CSS and OS rates were 73.6 [62.8-86.2]%, 68.1 [54.6-85]%, 82.5 [72-94.4]% and 75.3 [63.4-89.5]%, respectively. CONCLUSION We report favorable perioperative and oncological outcomes with expected decrease in renal function after robot-assisted RNU for patients with UTUC.
Collapse
Affiliation(s)
- Pierre-Etienne Gabriel
- Department of Urology, Pitié Salpêtrière Hospital, APHP, GRC 5, Predictive Onco-Urology, Sorbonne University, 47-83 Boulevard de l'Hôpital, 75013, Paris, France
| | - Ugo Pinar
- Department of Urology, Pitié Salpêtrière Hospital, APHP, GRC 5, Predictive Onco-Urology, Sorbonne University, 47-83 Boulevard de l'Hôpital, 75013, Paris, France
| | - Louis Lenfant
- Department of Urology, Pitié Salpêtrière Hospital, APHP, GRC 5, Predictive Onco-Urology, Sorbonne University, 47-83 Boulevard de l'Hôpital, 75013, Paris, France
| | - Jérôme Parra
- Department of Urology, Pitié Salpêtrière Hospital, APHP, GRC 5, Predictive Onco-Urology, Sorbonne University, 47-83 Boulevard de l'Hôpital, 75013, Paris, France
| | - Christophe Vaessen
- Department of Urology, Pitié Salpêtrière Hospital, APHP, GRC 5, Predictive Onco-Urology, Sorbonne University, 47-83 Boulevard de l'Hôpital, 75013, Paris, France
| | - Pierre Mozer
- Department of Urology, Pitié Salpêtrière Hospital, APHP, GRC 5, Predictive Onco-Urology, Sorbonne University, 47-83 Boulevard de l'Hôpital, 75013, Paris, France
| | - Emmanuel Chartier-Kastler
- Department of Urology, Pitié Salpêtrière Hospital, APHP, GRC 5, Predictive Onco-Urology, Sorbonne University, 47-83 Boulevard de l'Hôpital, 75013, Paris, France
| | - Morgan Rouprêt
- Department of Urology, Pitié Salpêtrière Hospital, APHP, GRC 5, Predictive Onco-Urology, Sorbonne University, 47-83 Boulevard de l'Hôpital, 75013, Paris, France
| | - Thomas Seisen
- Department of Urology, Pitié Salpêtrière Hospital, APHP, GRC 5, Predictive Onco-Urology, Sorbonne University, 47-83 Boulevard de l'Hôpital, 75013, Paris, France.
| |
Collapse
|
7
|
Lenfant L, Pinar U, Roupret M, Mozer P, Chartier-Kastler E, Seisen T. Role of Antimuscarinics Combined With Alpha-blockers in the Management of Urinary Storage Symptoms in Patients With Benign Prostatic Hyperplasia: An Updated Systematic Review and Meta-analysis. Reply. J Urol 2023; 210:34-35. [PMID: 37053541 DOI: 10.1097/ju.0000000000003485] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2023] [Accepted: 04/10/2023] [Indexed: 04/15/2023]
Affiliation(s)
- Louis Lenfant
- Department of Urology, Academic Hospital Pitié-Salpêtrière, Sorbonne Université, APHP, Paris, France
| | - Ugo Pinar
- Department of Urology, Academic Hospital Pitié-Salpêtrière, Sorbonne Université, APHP, Paris, France
| | - Morgan Roupret
- Department of Urology, Academic Hospital Pitié-Salpêtrière, Sorbonne Université, APHP, Paris, France
| | - Pierre Mozer
- Department of Urology, Academic Hospital Pitié-Salpêtrière, Sorbonne Université, APHP, Paris, France
| | - Emmanuel Chartier-Kastler
- Department of Urology, Academic Hospital Pitié-Salpêtrière, Sorbonne Université, APHP, Paris, France
| | - Thomas Seisen
- Department of Urology, Academic Hospital Pitié-Salpêtrière, Sorbonne Université, APHP, Paris, France
| |
Collapse
|
8
|
Bazinet A, Vaessen C, Mozer P, Popelin MB, Rod X, Chartier-Kastler E. Robotic-assisted artificial urinary sphincter revisions for women suffering from non-neurogenic stress incontinence: a single center experience. World J Urol 2023:10.1007/s00345-023-04399-8. [PMID: 37055589 DOI: 10.1007/s00345-023-04399-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2022] [Accepted: 04/01/2023] [Indexed: 04/15/2023] Open
Abstract
PURPOSE Patients with artificial urinary eventually need surgical revision. Unfortunately, in women, this requires another invasive abdominal intervention. Robotic-assisted revision may provide a less invasive and more acceptable approach for sphincter revision in women. We wanted to determinate the continence status after robotic-assisted artificial urinary sphincter revision among women with stress incontinence. We also examined postoperative complications and the safety of the procedure. METHODS The chart of the 31 women with stress urinary incontinence who underwent robotic-assisted AUS revision at our referral center from January 2015 to January 2022 were reviewed retrospectively. All patients underwent a robotic-assisted artificial urinary sphincter revision by one of our two expert surgeons. The primary outcome was to determinate the continence rate after revision and the secondary outcome aimed to evaluate the safety and feasibility of the procedure. RESULTS Mean patients age was 65 years old, and the mean time between the sphincter revision and previous implantation was 98 months. After a mean follow-up of 35 months, 75% of the patients were fully continent (0-pad). Moreover, 71% of the women were back to the same continence status as with the previously functional sphincter, while 14% even have an improved continence status. Clavien-Dindo grade [Formula: see text] 3 and overall complications occurred in 9% and 20.5% of our patients, respectively. This study is mainly limited by its retrospective design. CONCLUSION Robotic-assisted AUS revision carries satisfying outcome in terms of continence and safety.
Collapse
Affiliation(s)
- Amélie Bazinet
- Urologie, Sorbonne Université, Hôpital Universitaire Pitié-Salpêtrière, 47-83 Boulevard de L'Hôpital, 75651, Paris Cedex 13, France.
- Department of Urology, University of Montreal, Maisonneuve-Rosemont Hospital, Montreal, Canada.
| | - Christophe Vaessen
- Urologie, Sorbonne Université, Hôpital Universitaire Pitié-Salpêtrière, 47-83 Boulevard de L'Hôpital, 75651, Paris Cedex 13, France
| | - Pierre Mozer
- Urologie, Sorbonne Université, Hôpital Universitaire Pitié-Salpêtrière, 47-83 Boulevard de L'Hôpital, 75651, Paris Cedex 13, France
| | - Marie-Bérénice Popelin
- Urologie, Sorbonne Université, Hôpital Universitaire Pitié-Salpêtrière, 47-83 Boulevard de L'Hôpital, 75651, Paris Cedex 13, France
| | - Xavier Rod
- Urologie, Sorbonne Université, Hôpital Universitaire Pitié-Salpêtrière, 47-83 Boulevard de L'Hôpital, 75651, Paris Cedex 13, France
| | - Emmanuel Chartier-Kastler
- Urologie, Sorbonne Université, Hôpital Universitaire Pitié-Salpêtrière, 47-83 Boulevard de L'Hôpital, 75651, Paris Cedex 13, France
| |
Collapse
|
9
|
Gabriel PE, Pinar U, Parra J, Vaessen C, Mozer P, Chartier-Kastler E, Rouprêt M, Seisen T. [Pathological pelvic lymph node involvement in muscle-invasive bladder cancer patients treated with radical cystectomy: A narrative review]. Prog Urol 2023; 33:145-154. [PMID: 36604248 DOI: 10.1016/j.purol.2022.12.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2022] [Revised: 12/06/2022] [Accepted: 12/19/2022] [Indexed: 01/05/2023]
Abstract
OBJECTIVE To perform a narrative review of the contemporary literature on the diagnosis, prognosis and adjuvant management of muscle-invasive bladder cancer (MIBC) patients with pathological pelvic lymph node involvement (pN+) at radical cystectomy. METHOD A narrative review of the contemporary literature available on Medline was conducted to report studies evaluating the diagnosis, prognosis and/or adjuvant treatments for MIBC patients with pN+ disease at radical cystectomy. RESULTS Open or robotic extended pelvic lymph node dissection up to the crossing of the ureter with common iliac vessels can enhance the diagnosis of pN+ MIBC, especially using separate packages for the submission of a maximum number of lymph nodes. The main prognosis factors for pN+ patients are the number of positive and retrieved lymph nodes, lymph node density, extranodal extension as well as lymph node metastasis diameter. Adjuvant chemotherapy is likely to prolong overall survival in pN+ patients treated with radical cystectomy alone while adjuvant immunotherapy using nivolumab has been shown to decrease the risk of recurrence in all pN+ patients, especially those with ypN+ disease after neoadjuvant chemotherapy followed by radical cystectomy. However, few data are currently available on the role of adjuvant radiation therapy, which remains currently experimental for these patients. CONCLUSION Multiple parameters have been reported to impact the diagnosis and prognosis of patients with pN+ MIBC at radical cystectomy. Adjuvant management is currently based on chemotherapy and immunotherapy with preliminary data on radiation therapy.
Collapse
Affiliation(s)
- P-E Gabriel
- Sorbonne université, GRC n(o) 5, onco-urologie prédictive, AP-HP, hôpital de la Pitié-Salpêtrière, service d'urologie, 75013 Paris, France.
| | - U Pinar
- Sorbonne université, GRC n(o) 5, onco-urologie prédictive, AP-HP, hôpital de la Pitié-Salpêtrière, service d'urologie, 75013 Paris, France
| | - J Parra
- Sorbonne université, GRC n(o) 5, onco-urologie prédictive, AP-HP, hôpital de la Pitié-Salpêtrière, service d'urologie, 75013 Paris, France
| | - C Vaessen
- Sorbonne université, GRC n(o) 5, onco-urologie prédictive, AP-HP, hôpital de la Pitié-Salpêtrière, service d'urologie, 75013 Paris, France
| | - P Mozer
- Sorbonne université, GRC n(o) 5, onco-urologie prédictive, AP-HP, hôpital de la Pitié-Salpêtrière, service d'urologie, 75013 Paris, France
| | - E Chartier-Kastler
- Sorbonne université, GRC n(o) 5, onco-urologie prédictive, AP-HP, hôpital de la Pitié-Salpêtrière, service d'urologie, 75013 Paris, France
| | - M Rouprêt
- Sorbonne université, GRC n(o) 5, onco-urologie prédictive, AP-HP, hôpital de la Pitié-Salpêtrière, service d'urologie, 75013 Paris, France
| | - T Seisen
- Sorbonne université, GRC n(o) 5, onco-urologie prédictive, AP-HP, hôpital de la Pitié-Salpêtrière, service d'urologie, 75013 Paris, France
| |
Collapse
|
10
|
Krings G, Ayoub E, Campi R, Rouprêt M, Vaessen C, Parra J, Mozer P. Ureteropelvic junction obstruction and renal calculi: Simultaneous treatment by robot-assisted laparoscopic pyeloplasty and transcutaneous retrograde flexible ureteroscopy. Technique description and early outcomes. Prog Urol 2023; 33:279-284. [PMID: 36792487 DOI: 10.1016/j.purol.2023.01.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2022] [Revised: 01/20/2023] [Accepted: 01/24/2023] [Indexed: 02/15/2023]
Abstract
BACKGROUND Ureteropelvic junction obstruction (UPJO) and renal calculi are associated in 20 to 30% of cases and treatment is mandatory. The simultaneous surgical management is a therapeutic challenge that is still a source of controversy. We describe our technique combining robot-assisted laparoscopic pyeloplasty and transcutaneous retrograde flexible ureteroscopy (fURS), assessing the feasibility of simultaneous treatment through an original technique. METHODS This single centre series reports our initial experience with 12 patients. From January 2014 to September 2018, 12 patients underwent robot-assisted laparoscopic pyeloplasty with simultaneous fURS for UPJO and renal calculi. Mean age was 46 years (24-68). 92% had multiple renal stones and the mean cumulative stone diameter was 31,3mm. Robot-assisted pyeloplasty was performed with peroperative transcutaneous retrograde fURS through a ureteral access sheath introduced in an incision on the bassinet through a subcostal trocar. Stone extraction was performed using a basket. RESULTS All patients underwent surgery successfully, achieving UPJ repair and complete stone extraction. Mean operating time was 92,5min (85-110). All reported Clavien-Dindo complications were grade 1. Non-contrast enhanced abdominal CT performed 1 month after surgery confirmed the absence of residual stones in all patients. Mean follow-up time was 10 months with no recurrence of UPJO. CONCLUSION This small series confirms the feasibility with good surgical results of concomitant robot-assisted laparoscopic pyeloplasty and transcutaneous retrograde fURS stone extraction. No major complications were observed. This technique is easily reproducible but requires 2 experienced urologists to be achieved in a contained operative time.
Collapse
Affiliation(s)
- G Krings
- Academic Department of Urology, AP-HP, Hôpital Pitié-Salpétrière, Paris, France; Urology Department, CHU UCL Namur, 1 Av Gaston Therasse, 5530 Yvoir, Belgium.
| | - E Ayoub
- Academic Department of Urology, AP-HP, Hôpital Pitié-Salpétrière, Paris, France.
| | - R Campi
- Academic Department of Urology, AP-HP, Hôpital Pitié-Salpétrière, Paris, France; Department of Urology, University of Florence, Careggi Hospital, Urology, Florence, Italy..
| | - M Rouprêt
- Academic Department of Urology, AP-HP, Hôpital Pitié-Salpétrière, Paris, France; Sorbonne Université, GRC n°5, ONCOTYPE-URO, AP-HP, Hôpital Pitié-Salpêtrière, 75013 Paris, France.
| | - C Vaessen
- Academic Department of Urology, AP-HP, Hôpital Pitié-Salpétrière, Paris, France.
| | - J Parra
- Academic Department of Urology, AP-HP, Hôpital Pitié-Salpétrière, Paris, France.
| | - P Mozer
- Academic Department of Urology, AP-HP, Hôpital Pitié-Salpétrière, Paris, France; Sorbonne Université, Institut des Systèmes Intelligents et de Robotique (ISIR) UPMC - CNRS/UMR 7222, 75005 Paris, France.
| |
Collapse
|
11
|
Lenfant L, Pinar U, Roupret M, Mozer P, Chartier-Kastler E, Seisen T. Role of Antimuscarinics Combined With Alpha-blockers in the Management of Urinary Storage Symptoms in Patients With Benign Prostatic Hyperplasia: An Updated Systematic Review and Meta-analysis. J Urol 2023; 209:314-324. [PMID: 36395428 DOI: 10.1097/ju.0000000000003077] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2022] [Accepted: 11/10/2022] [Indexed: 11/18/2022]
Abstract
PURPOSE We evaluate the efficacy and safety of combining antimuscarinics with alpha-blockers to treat storage symptoms in men with benign prostatic hyperplasia. MATERIALS AND METHODS Searches were carried out on PubMed, MEDLINE, EMBASE, and Cochrane databases to identify randomized, placebo-controlled trials published before February 15, 2022, assessing the efficacy or safety of antimuscarinics in men with benign prostatic hyperplasia treated with alpha-blockers. Further meta-analyses were performed using standardized mean difference and risk ratio. RESULTS A total of 12 randomized trials were included in the systematic review. The meta-analysis showed no impact of antimuscarinics on the number of urgencies per day (SMD -0.23 [95%CI: -0.64; -0.17]; P = .21). However, the use of antimuscarinics was associated with a small reduction of micturition episodes per day (SMD -0.19 [95%CI: -0.37; -0.01]; P = .045). With regard to side effects, post-void residual increased slightly in patients treated with antimuscarinics (SMD 0.26 [95%CI: 0.15; 0.37]; P < .01). In addition, there was a higher risk of acute urinary retention (RR 3.26 [95%CI: 1.35; 7.86]; P = .02), dry mouth (RR 3.43 [95%CI: 1.86; 6.32]; P < .001), and constipation (RR 2.92 [95%CI: 1.48; 5.73]; P < .001) with the use of antimuscarinics. Finally, the risk of treatment interruption due to adverse events was higher for the patients treated with antimuscarinics (RR 1.74 [95%CI: 1.27; 2.38]; P < .01). CONCLUSIONS The addition of antimuscarinics to alpha-blockers was not associated with a substantial reduction in urgencies and micturition episodes in benign prostatic hyperplasia patients with storage symptoms. In addition, the toxicity profile was not in favor of antimuscarinic use in these patients.
Collapse
Affiliation(s)
- Louis Lenfant
- Department of Urology, Academic Hospital Pitié-Salpêtrière, Sorbonne Université, APHP, Paris, France
| | - Ugo Pinar
- Department of Urology, Academic Hospital Pitié-Salpêtrière, Sorbonne Université, APHP, Paris, France
| | - Morgan Roupret
- Department of Urology, Academic Hospital Pitié-Salpêtrière, Sorbonne Université, APHP, Paris, France
| | - Pierre Mozer
- Department of Urology, Academic Hospital Pitié-Salpêtrière, Sorbonne Université, APHP, Paris, France
| | - Emmanuel Chartier-Kastler
- Department of Urology, Academic Hospital Pitié-Salpêtrière, Sorbonne Université, APHP, Paris, France
| | - Thomas Seisen
- Department of Urology, Academic Hospital Pitié-Salpêtrière, Sorbonne Université, APHP, Paris, France
| |
Collapse
|
12
|
Lenfant L, Mozer P, Seisen T. Re: Jonas Hugosson, Marianne Månsson, Jona Wallström, et al. Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only. N Engl J Med 2022;387:2126-37. Eur Urol Oncol 2023; 6:235. [PMID: 36707321 DOI: 10.1016/j.euo.2023.01.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2023] [Accepted: 01/14/2023] [Indexed: 01/26/2023]
Affiliation(s)
- Louis Lenfant
- Sorbonne University, GRC n°5, Predictive Onco-Urology, AP-HP, Pitié-Salpêtrière Hospital, Paris, France.
| | - Pierre Mozer
- Sorbonne University, GRC n°5, Predictive Onco-Urology, AP-HP, Pitié-Salpêtrière Hospital, Paris, France
| | - Thomas Seisen
- Sorbonne University, GRC n°5, Predictive Onco-Urology, AP-HP, Pitié-Salpêtrière Hospital, Paris, France
| |
Collapse
|
13
|
Cotte J, Dechartres A, Mozer P, Poinard F, Chartier-Kastler E, Beaugerie A. Long-term device survival after a first implantation of AMS800™ for stress urinary incontinence: Comparison between men and women. Neurourol Urodyn 2023; 42:80-89. [PMID: 36183390 DOI: 10.1002/nau.25047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2022] [Revised: 08/24/2022] [Accepted: 08/31/2022] [Indexed: 01/03/2023]
Abstract
PURPOSE The artificial urinary sphincter is the reference treatment for stress urinary incontinence in men, but it remains rarely used in women. This study aimed to compare long-term device survival between women and men, after the first implantation of an AMS800™ artificial urinary sphincter (Boston Scientific) for the treatment of a non-neurogenic stress urinary incontinence. MATERIALS AND METHODS This retrospective cohort study included all patients with nonneurogenic stress urinary incontinence who underwent surgery in a large-volume university hospital between 2000 and 2013. The primary outcome was the overall survival of the device, defined as the absence of any repeated surgery (revision or explantation) during follow-up. Men and women were matched 3:1 according to age and year of implantation. Differences were analyzed using a Cox model accounting for matching and applying time intervals because hazards were not proportional over time. Sensitivity analyzes were performed, excluding firstly a population with a history of radiotherapy and secondly a population with more than one previous surgery for urinary incontinence. RESULTS A total of 107 women were matched to 316 men. Median follow-up was 6.0 years (Q1-Q3 1.8-9.4): 7.0 years (Q1-Q3 3.1-10.3) for women and 5.1 years (Q1-Q3 1.3-9.1) for men. During the follow-up, 56 patients had an explantation of the device: 44 men (13.9%) and 12 women (11.2%), and 113 had a revision: 85 men (26.9%) and 28 women (26.1%). Men have a significantly higher risk of explantation or revision than women between 6 months and 8 years after implantation (hazard ratio 2.12 [1.29-3.48]). Before 6 months and after 8 years, there were no significant differences. Both sensitivity analyses found consistent results. CONCLUSIONS This study suggests that device survival seems better in women after the first 6 months.
Collapse
Affiliation(s)
- Juliette Cotte
- Department of Urology, Pitié-Salpêtrière Academic Hospital, Assistance Publique-Hôpitaux Paris, Sorbonne Université, Paris, France
| | - Agnès Dechartres
- Département de Santé Publique, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpital Pitié Salpêtrière, Sorbonne Université, Paris, France
| | - Pierre Mozer
- Department of Urology, Pitié-Salpêtrière Academic Hospital, Assistance Publique-Hôpitaux Paris, Sorbonne Université, Paris, France
| | - Florence Poinard
- Department of Urology, Pitié-Salpêtrière Academic Hospital, Assistance Publique-Hôpitaux Paris, Sorbonne Université, Paris, France
| | - Emmanuel Chartier-Kastler
- Department of Urology, Pitié-Salpêtrière Academic Hospital, Assistance Publique-Hôpitaux Paris, Sorbonne Université, Paris, France
| | - Aurélien Beaugerie
- Department of Urology, Pitié-Salpêtrière Academic Hospital, Assistance Publique-Hôpitaux Paris, Sorbonne Université, Paris, France
| |
Collapse
|
14
|
Beaugerie A, Poinard F, Denormandie A, Cotte J, Reus C, Mozer P, Chartier-Kastler E. Comparative urodynamic study in cadaver of urethral pressure profilometry between the UroMems artificial urinary sphincter and the AMS800™. Eur Urol 2022. [DOI: 10.1016/s0302-2838(22)00668-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
15
|
Beaugerie A, Poinard F, Cotte J, Denormandie A, Reus C, Mozer P, Chartier-Kastler E. Preclinical evaluation of a novel artificial urinary sphincter in a wether model. Eur Urol 2022. [DOI: 10.1016/s0302-2838(22)01269-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
16
|
Lenfant L, Beaugerie A, Renard-Penna R, Seisen T, Rouprêt M, Conort P, Comperat E, Rouvier P, Chartier-Kastler E, Mozer P. Évaluation sur 10 ans des biopsies ciblées pour le diagnostic du cancer de la prostate : une étude monocentrique prospective. Prog Urol 2021. [DOI: 10.1016/j.purol.2021.08.072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
17
|
Beaugerie A, Poinard F, Denormandie A, Cotte J, Reus C, Chartier-Kastler E, Mozer P. Étude comparative urodynamique des pressions de clôture urétrale chez le sujet anatomique entre le sphincter urinaire UroMems et l’AMS800. Prog Urol 2021. [DOI: 10.1016/j.purol.2021.08.095] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
18
|
Reus C, Brattås I, Volz D, Sydén F, Grufman KH, Mozer P, Renström-Koskela L. Evaluation of the 24-h pad weight test as continence rate assessment tool after artificial urinary sphincter implantation for postprostatectomy urinary incontinence: A Swedish retrospective cohort study. Neurourol Urodyn 2021; 40:1585-1592. [PMID: 34082480 DOI: 10.1002/nau.24723] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2020] [Revised: 04/26/2021] [Accepted: 05/13/2021] [Indexed: 11/06/2022]
Abstract
AIM Patient-reported pad-count as continence rate assessment tool after artificial urinary sphincter (AUS) implantation is common. However, lack of standardized continence definition using this method results in heterogeneous published efficacy outcomes. Data on 24-h pad weight tests (PWT) after primary AUS implantation for postprostatectomy urinary incontinence (PPUI) is scarce. Our aim was to evaluate the 24-h PWT as an efficacy assessment tool and correlate it to qualitative outcomes using validated questionnaires. METHODS This retrospective, single center, follow-up cohort study, evaluated 180 patients who underwent primary AUS implantation for PPUI from 2005 to 2018. Voiding diaries, 24-h PWT, validated patient satisfaction and quality of life (QoL) questionnaires were collected pre-operatively and at 3-6 months postactivation, using the institution's Electronic Medical Records. RESULTS The median preoperative and postoperative 24-h PWT values were 494 (interquartile range [IQR]: 304-780) and 7 (IQR: 0-25) g respectively with a significant improvement in urinary leakage of 489.5 g 99.1% (p < 0.001). Median preoperative and postoperative I-QoL results increased from 33.5 (IQR: 19.3-63.6) to 86.4 (IQR: 73.9-94.3) points, with a significant 52.9 points improvement in QoL (p < 0.001). Similarly, the median preoperative and postoperative ICIQ-SF values decreased from 20 (IQR: 17-21) to 5 (IQR: 3-9) points, showing a significant improvement of 15 points (p < 0.001). We also found a significant correlation between PWT and patient satisfaction. CONCLUSION The 24-h PWT provides a reliable and objective assessment of continence rates, with a strong correlation to qualitative outcomes, after primary AUS implantation for PPUI. Its use could help reduce reported outcome heterogeneity across studies.
Collapse
Affiliation(s)
- Christine Reus
- Section of Urology, Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.,Department of Pelvic cancer, Karolinska University Hospital, Stockholm, Sweden
| | - Izabelle Brattås
- Department of Pelvic cancer, Karolinska University Hospital, Stockholm, Sweden
| | - Daniela Volz
- Department of Pelvic cancer, Karolinska University Hospital, Stockholm, Sweden
| | - Filip Sydén
- Section of Urology, Södersjukhuset Hospital, Stockholm, Sweden
| | - Katarina Hallén Grufman
- Section of Urology, Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden
| | - Pierre Mozer
- Department of Urology, Academic Hospital Pitié-Salpétrière, AP-HP, Paris Sorbonne University, Paris, France
| | - Lotta Renström-Koskela
- Section of Urology, Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.,Department of Pelvic cancer, Karolinska University Hospital, Stockholm, Sweden
| |
Collapse
|
19
|
Pinar U, Clerget A, Perrot O, Beaud N, Akakpo W, Ruggiero M, Parra J, Vaessen C, Guillot-Tantay C, Conort P, Campedel L, Girault J, Simon J, Maingon P, Renard-Penna R, Mozer P, Chartier-Kastler E, Roupret M, Seisen T. Assessment of physicians’ satisfaction with a virtual tumour board in a French academic centre during the COVID-19 pandemic. Eur Urol 2021. [DOI: 10.1016/s0302-2838(21)01362-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
20
|
Frydman V, Pinar U, Abdessater M, Akakpo W, Grande P, Audouin M, Mozer P, Chartier-Kastler E, Seisen T, Roupret M. Long-term outcomes after penile prosthesis placement for the Management of Erectile Dysfunction: a single-Centre experience. Basic Clin Androl 2021; 31:4. [PMID: 33658014 PMCID: PMC7931532 DOI: 10.1186/s12610-021-00123-x] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2020] [Accepted: 01/18/2021] [Indexed: 11/11/2022] Open
Abstract
Background Penile prothesis (PP) is the gold-standard treatment of drug-refractory erectile dysfunction (ED). While postoperative outcomes have been widely described in the literature, there are few data about patient satisfaction and intraoperative events. We aimed to assess long-term patient satisfaction and perioperative outcomes after PP implantation in a single-centre cohort of unselected patients using validated scales. Results A total of 130 patients received a PP (median age: 62.5 years [IQR: 58–69]; median International Index of Erectile Function (IEEF-5) score: 6 [IQR: 5–7]). Median follow-up was 6.3 years [IQR: 4–9.4]. Thirty-two (24.6%) patients underwent surgical revision, of which 20 were PP removals (15.4%). Global PP survival rate was 84.6% and previous PP placement was a risk factor for PP removal (p = 0.02). There were six (4.6%) non-life-threatening intraoperative events including two which resulted in non-placement of a PP (1.5%). EAUiaic grade was 0 for 124 procedures (95.4%), 1 for four procedures (3.1%) and 2 for two procedures (1.5%). Of patients who still had their PP at the end of the study, 91 (80.5%) expressed satisfaction. Conclusions PP implantation is a last-resort treatment for ED with a satisfactory outcome. PPs are well accepted by patients.
Collapse
Affiliation(s)
- Valentine Frydman
- Department of Urology, Sorbonne Université, GRC n 5, Predictive Onco-Urology, APHP, Hôpital Pitié-Salpêtrière, F-75013, Paris, France
| | - Ugo Pinar
- Department of Urology, Sorbonne Université, GRC n 5, Predictive Onco-Urology, APHP, Hôpital Pitié-Salpêtrière, F-75013, Paris, France
| | - Maher Abdessater
- Department of Urology, Sorbonne Université, GRC n 5, Predictive Onco-Urology, APHP, Hôpital Pitié-Salpêtrière, F-75013, Paris, France
| | - William Akakpo
- Department of Urology, Sorbonne Université, APHP, Hôpitaux universitaires Pitié-Salpêtrière-Charles Foix, F-75013, Paris, France
| | - Pietro Grande
- Department of Urology, Sorbonne Université, APHP, Hôpitaux universitaires Pitié-Salpêtrière-Charles Foix, F-75013, Paris, France
| | - Marie Audouin
- Department of Urology, Sorbonne Université, APHP, Hôpital Tenon, F-75013, Paris, France
| | - Pierre Mozer
- Department of Urology, Sorbonne Université, APHP, Hôpitaux universitaires Pitié-Salpêtrière-Charles Foix, F-75013, Paris, France
| | - Emmanuel Chartier-Kastler
- Department of Urology, Sorbonne Université, APHP, Hôpitaux universitaires Pitié-Salpêtrière-Charles Foix, F-75013, Paris, France
| | - Thomas Seisen
- Department of Urology, Sorbonne Université, GRC n 5, Predictive Onco-Urology, APHP, Hôpital Pitié-Salpêtrière, F-75013, Paris, France
| | - Morgan Roupret
- Department of Urology, Sorbonne Université, GRC n 5, Predictive Onco-Urology, APHP, Hôpital Pitié-Salpêtrière, F-75013, Paris, France.
| |
Collapse
|
21
|
Hamzaoui D, Montagne S, Mozer P, Renard-Penna R, Delingette H. Segmentation automatique de la prostate à l’aide d’un réseau de neurones profond. Prog Urol 2020. [DOI: 10.1016/j.purol.2020.07.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
22
|
Abstract
Upper tract urinary carcinoma (UTUC) is a heterogeneous group of rare tumors. The aim of this article is to critically review current therapeutic strategies and to propose a change in the risk-stratification of the disease. A non-systematic review of the literature was performed using the Medline database with the search terms: “upper tract urothelial carcinoma” together with “prognostic factor”, “risk stratification”, “risk factor”, “recurrence”, “predictive tool”, “nomograms” and “treatment”. Preoperative risk factors can be viewed as patient-related risk factors (gender, age, ethnicity, body mass index, smoking status, or genetic factors), or tumor-related risk factors (stage, grade, size, architecture, multifocality, ureteric obstruction). Several biomarkers, available either in blood, urine, or the tumor itself have also been proposed. However, many of these prognostic factors lack accuracy and validation in predicting oncological outcomes, despite their use in predictive tools. After risk stratification, kidney-sparing strategies should be considered (endoscopic management and segmental ureterectomy) and could benefit from new diagnostic tools and technical improvements in in situ adjuvant endocavitary instillations. Radical nephroureterectomy remains the first choice therapy for high-grade disease and will probably be associated with other treatments in the future (lymphadenectomy, perioperative chemotherapy, or immunotherapy). In view of the major recent improvements in UTUC treatment strategies, a new classification should be proposed, including low-, intermediate-, high- and very high-risk disease. Subgroup analysis of good quality trials and better understanding of UTUC risk factors will help validate this new approach toward more personalized medicine.
Collapse
Affiliation(s)
- Daniel Benamran
- Division of Urology, Geneva University Hospitals, Geneva, Switzerland.,Sorbonne Université, GRC n°5, ONCOTYPE-URO, AP-HP, Urology Department, Hôpital Pitié-Salpêtrière, F-75013 Paris, France
| | - Thomas Seisen
- Sorbonne Université, GRC n°5, ONCOTYPE-URO, AP-HP, Urology Department, Hôpital Pitié-Salpêtrière, F-75013 Paris, France
| | - Elias Naoum
- Sorbonne Université, GRC n°5, ONCOTYPE-URO, AP-HP, Urology Department, Hôpital Pitié-Salpêtrière, F-75013 Paris, France
| | - Christophe Vaessen
- Sorbonne Université, GRC n°5, ONCOTYPE-URO, AP-HP, Urology Department, Hôpital Pitié-Salpêtrière, F-75013 Paris, France
| | - Jérome Parra
- Sorbonne Université, GRC n°5, ONCOTYPE-URO, AP-HP, Urology Department, Hôpital Pitié-Salpêtrière, F-75013 Paris, France
| | - Pierre Mozer
- Sorbonne Université, GRC n°5, ONCOTYPE-URO, AP-HP, Urology Department, Hôpital Pitié-Salpêtrière, F-75013 Paris, France
| | | | - Morgan Rouprêt
- Sorbonne Université, GRC n°5, ONCOTYPE-URO, AP-HP, Urology Department, Hôpital Pitié-Salpêtrière, F-75013 Paris, France
| |
Collapse
|
23
|
Dardenne E, Manach Q, Grande P, Campi R, Gomez F, Granger B, Misrai V, Bitker MO, Mozer P, Roupret M. Satisfaction and surgical outcomes in patients undergoing penile prosthesis implantation for drug-refractory erectile dysfunction: mid-term results in a single center French cohort. Can J Urol 2019; 26:10039-10044. [PMID: 31860421] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]
Abstract
INTRODUCTION To investigate the mid-term results of penile prosthesis (PP) implantation in patients with erectile dysfunction (ED) from a "real-life" historic cohort in a French academic center. MATERIALS AND METHODS All patients receiving an inflatable PP between 2004 and 2014 in our institution were included in this study. ED was assessed preoperatively using the IEEF-5 questionnaire. Postoperative satisfaction with the PP was assessed using the EDITS questionnaire at each follow up visit. Postoperative complications were classed according to the Clavien classification. Surgical and functional outcomes were recorded prospectively. RESULTS Seventy-six men received a PP during the 10 year study period. Median (IQR) age was 62 (58-69) years. The main causes of ED were radical prostatectomy (n = 40; 53%) and diabetes mellitus (n = 28; 36.8%). Five patients (6.6%) had a non-functioning PP in place requiring complete substitution or a previous penile implant which had already been removed at the time of surgery. Sixty-nine (90.8%) patients received an AMS 700 CX device and seven (9.2%) a Coloplast Titan. The surgical approach was penoscrotal in 45 (59.2%) and infrapubic in 31 (40.8%). Intraoperative complications occurred in four (5%) patients, without compromising the intervention. Postoperative complications occurred in 27 (35.5%) patients: 17 (22%) were Clavien I-II and 10 (15%) Clavien III. All major complications resulted in prosthesis removal (n = 9; 11.8%) or revision (n = 1; 1.3%). Median (IQR) follow up was 43 (34-55) months. At the end of follow up, 70 (92.1%) patients had a functional implant. Fifty-four (71.1%) patients were satisfied with the device at the 6 month follow up visit and beyond. Early satisfaction (at 3 months) was reported by 44 (57.9%) patients. A previous PP was the only significant risk factor for prosthesis removal (p = 0.001). CONCLUSION PP implantation is a safe and satisfactory treatment for ED. However, patient selection remains crucial in determining the post-surgical success of this procedure.
Collapse
Affiliation(s)
- Emilie Dardenne
- Sorbonne Universite, GRC no5, ONCOTYPE-URO, AP-HP, Urology, Hopital Pitie-Salpetriere, F-75013 Paris, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Oderda M, Marra G, Albisinni S, Altobelli E, Baco E, Beatrici V, Dellabella M, Descotes JL, Eldred-Evans D, Fasolis G, Ferriero M, Fiard G, Giacobbe A, Kumar P, Lacetera V, Mozer P, Muto G, Papalia R, Peltier A, Piechaud T, Pierangeli T, Simone G, Roche JB, Roupret M, Gontero P. Elastic fusion biopsy versus systematic biopsy for prostate cancer detection: Results of a multicentric study on 1,119 patients. Actas Urol Esp 2019; 43:431-438. [PMID: 31155373 DOI: 10.1016/j.acuro.2019.01.009] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2018] [Accepted: 01/04/2019] [Indexed: 11/29/2022]
Abstract
OBJECTIVES To assess the accuracy of targeted and systematic biopsies for the detection of prostate cancer (PCa) and clinically significant PCa (csPCa) in the everyday practice, evaluating the need for additional systematic biopsies at the time of targeted biopsy. PATIENTS AND METHODS From our multicentric database gathering data on 2,115 patients who underwent fusion biopsy with Koelis™ system between 2010 and 2017, we selected 1,119 patients who received targeted biopsies (a median of 3 for each target), followed by systematic sampling of the prostate (12 to 14 cores). Overall and clinically significant cancer detection rate (CDR) of Koelis™ fusion biopsies were assessed, comparing target and systematic biopsies. Secondary endpoint was the identification of predictors of PCa detection. RESULTS The CDR of targeted biopsies only was 48% for all cancers and 33% for csPCa. The performance of additional, systematic prostate sampling improved the CDR of 15% for all cancers and of 12% for csPCa. PCa was detected in 35%, 69%, and 92% of patients with lesions scored as PI-RADS 3, 4 and 5, respectively. Elevated PI-RADS score and positive digital rectal examination were predictors of PCa, whereas biopsy-naïve status was associated with csPCa. CONCLUSION In the everyday practice target biopsy with Koelis™ achieves a good CDR for all PCa and csPCa, which is significantly improved by subsequent systematic sampling of the prostate. The outstanding outcomes of fusion biopsy are confirmed also in biopsy-naïve patients. Elevated PI-RADS score and positive digital rectal examination are strongly associated with presence of PCa.
Collapse
Affiliation(s)
- M Oderda
- Departamento de Ciencias Quirúrgicas, Urología, Universitad de Turín, Turín, Italia; Departamento de Urología, Hospital San Lázaro, Alba, Italia.
| | - G Marra
- Departamento de Ciencias Quirúrgicas, Urología, Universitad de Turín, Turín, Italia
| | - S Albisinni
- Departamento de Urología, Hospital Eraste, Universidad Libre de Bruselas, Bruselas, Bélgica
| | - E Altobelli
- Departamento de Urología, Campus Biomédico Universidad, Roma, Italia
| | - E Baco
- Departamento de Urología, Hospital Universitario de Oslo, Oslo, Noruega
| | - V Beatrici
- Departamento de Urología, Azienda Ospedaliera Ospedali Riuniti Marche Nord, Pesaro-Fano, Italia
| | - M Dellabella
- Departamento de Urología, INRCA-IRCCS, Ancona, Italia
| | - J L Descotes
- Departamento de Urología, Centre Hospitalier Universitaire de Grenoble, Grenoble, Francia
| | - D Eldred-Evans
- Departamento de Urología, Hospital Royal Marsden, Londres, Reino Unido
| | - G Fasolis
- Departamento de Urología, Hospital San Lázaro, Alba, Italia
| | - M Ferriero
- Departamento de Urología, Regina Elena National Cancer Institute, Roma, Italia
| | - G Fiard
- Departamento de Urología, Centre Hospitalier Universitaire de Grenoble, Grenoble, Francia
| | - A Giacobbe
- Departamento de Urología, Humanitas Gradenigo Hospital, Turín, Italia
| | - P Kumar
- Departamento de Urología, Hospital Royal Marsden, Londres, Reino Unido
| | - V Lacetera
- Departamento de Urología, Azienda Ospedaliera Ospedali Riuniti Marche Nord, Pesaro-Fano, Italia
| | - P Mozer
- Departamento de Urología, Pitié Salpétrière Hospital, Assistance Publique - Hôpitaux de Paris, Universités Paris Sorbonne, París, Francia
| | - G Muto
- Departamento de Urología, Humanitas Gradenigo Hospital, Turín, Italia
| | - R Papalia
- Departamento de Urología, Campus Biomédico Universidad, Roma, Italia
| | - A Peltier
- Departamento de Urología, Instituto Jules Bordet, Universidad Libre de Bruselas, Bruselas, Bélgica
| | - T Piechaud
- Departamento de Urología, Clinique Saint Augustin, Burdeos, Francia
| | - T Pierangeli
- Unidad de Cáncer de Próstata, INRCA-IRCCS, Ancona, Italia
| | - G Simone
- Departamento de Urología, Regina Elena National Cancer Institute, Roma, Italia
| | - J B Roche
- Departamento de Urología, Clinique Saint Augustin, Burdeos, Francia
| | - M Roupret
- Departamento de Urología, Pitié Salpétrière Hospital, Assistance Publique - Hôpitaux de Paris, Universités Paris Sorbonne, París, Francia
| | - P Gontero
- Departamento de Ciencias Quirúrgicas, Urología, Universitad de Turín, Turín, Italia
| |
Collapse
|
25
|
Oderda M, Marra G, Albisinni S, Altobelli E, Baco E, Beatrici V, Cantiani A, Carbone A, Ciccariello M, Descotes JL, Dubreuil-Chambardel M, Eldred-Evans D, Fasolis G, Ferriero M, Fiard G, Forte V, Giacobbe A, Kumar P, Lacetera V, Mozer P, Muto G, Papalia R, Pastore A, Peltier A, Piechaud T, Simone G, Roche JB, Roupret M, Rouviere O, Van Velthoven R, Gontero P. Accuracy of elastic fusion biopsy in daily practice: Results of a multicenter study of 2115 patients. Int J Urol 2018; 25:990-997. [PMID: 30187529 DOI: 10.1111/iju.13796] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2018] [Accepted: 08/05/2018] [Indexed: 12/21/2022]
Abstract
OBJECTIVES To assess the accuracy of Koelis fusion biopsy for the detection of prostate cancer and clinically significant prostate cancer in the everyday practice. METHODS We retrospectively enrolled 2115 patients from 15 institutions in four European countries undergoing transrectal Koelis fusion biopsy from 2010 to 2017. A variable number of target (usually 2-4) and random cores (usually 10-14) were carried out, depending on the clinical case and institution habits. The overall and clinically significant prostate cancer detection rates were assessed, evaluating the diagnostic role of additional random biopsies. The cancer detection rate was correlated to multiparametric magnetic resonance imaging features and clinical variables. RESULTS The mean number of targeted and random cores taken were 3.9 (standard deviation 2.1) and 10.5 (standard deviation 5.0), respectively. The cancer detection rate of Koelis biopsies was 58% for all cancers and 43% for clinically significant prostate cancer. The performance of additional, random cores improved the cancer detection rate of 13% for all cancers (P < 0.001) and 9% for clinically significant prostate cancer (P < 0.001). Prostate cancer was detected in 31%, 66% and 89% of patients with lesions scored as Prostate Imaging Reporting and Data System 3, 4 and 5, respectively. Clinical stage and Prostate Imaging Reporting and Data System score were predictors of prostate cancer detection in multivariate analyses. Prostate-specific antigen was associated with prostate cancer detection only for clinically significant prostate cancer. CONCLUSIONS Koelis fusion biopsy offers a good cancer detection rate, which is increased in patients with a high Prostate Imaging Reporting and Data System score and clinical stage. The performance of additional, random cores seems unavoidable for correct sampling. In our experience, the Prostate Imaging Reporting and Data System score and clinical stage are predictors of prostate cancer and clinically significant prostate cancer detection; prostate-specific antigen is associated only with clinically significant prostate cancer detection, and a higher number of biopsy cores are not associated with a higher cancer detection rate.
Collapse
Affiliation(s)
- Marco Oderda
- Department of Surgical Sciences - Urology, University of Turin, Turin, Italy.,Department of Urology, San Lazzaro Hospital, Alba, Italy
| | - Giancarlo Marra
- Department of Surgical Sciences - Urology, University of Turin, Turin, Italy
| | - Simone Albisinni
- Department of Urology, Hopital Erasme, Université Libre de Bruxelles, Brussels, Belgium
| | | | - Eduard Baco
- Department of Urology, Oslo University Hospital, Oslo, Norway
| | - Valerio Beatrici
- Department of Urology, Azienda Ospedaliera Ospedali Riuniti Marche Nord, Pesaro-Fano, Italy
| | | | - Antonio Carbone
- Department of Medico-Surgical Sciences and Biotechnologies, Urology Unit, Sapienza University of Rome, Latina, Italy
| | - Mauro Ciccariello
- Department of Radiological, Oncological and Anatomo-Pathological Sciences, Sapienza University of Rome, Rome, Italy
| | - Jean-Luc Descotes
- Department of Urology, Centre Hospitalier Universitaire de Grenoble, Grenoble, France
| | - Marine Dubreuil-Chambardel
- Hospices Civils de Lyon, Department of Urinary and Vascular Radiology, Hôpital Edouard Herriot, Université de Lyon, Lyon, France
| | | | | | | | - Gaelle Fiard
- Department of Urology, Centre Hospitalier Universitaire de Grenoble, Grenoble, France
| | - Valerio Forte
- Department of Radiological, Oncological and Anatomo-Pathological Sciences, Sapienza University of Rome, Rome, Italy
| | | | - Pardeep Kumar
- Department of Urology, Royal Marsden Hospital, London, UK
| | - Vito Lacetera
- Department of Urology, Azienda Ospedaliera Ospedali Riuniti Marche Nord, Pesaro-Fano, Italy
| | - Pierre Mozer
- Department of Urology, Pitié Salpétrière Hospital, Assistance Publique - Hôpitaux de Paris, Universités Paris Sorbonne, Paris, France
| | - Giovanni Muto
- Department of Urology, Humanitas Gradenigo Hospital, Turin, Italy
| | - Rocco Papalia
- Department of Urology, Campus Biomedico University, Rome, Italy
| | - Antonio Pastore
- Department of Medico-Surgical Sciences and Biotechnologies, Urology Unit, Sapienza University of Rome, Latina, Italy
| | - Alexandre Peltier
- Department of Urology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
| | - Thierry Piechaud
- Department of Urology, Clinique Saint Augustin, Bordeaux, France
| | - Giuseppe Simone
- Department of Urology, Regina Elena National Cancer Institute, Rome, Italy
| | | | - Morgan Roupret
- Department of Urology, Pitié Salpétrière Hospital, Assistance Publique - Hôpitaux de Paris, Universités Paris Sorbonne, Paris, France
| | - Olivier Rouviere
- Hospices Civils de Lyon, Department of Urinary and Vascular Radiology, Hôpital Edouard Herriot, Université de Lyon, Lyon, France
| | - Roland Van Velthoven
- Department of Urology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
| | - Paolo Gontero
- Department of Surgical Sciences - Urology, University of Turin, Turin, Italy
| |
Collapse
|
26
|
Tavolaro S, Mozer P, Roupret M, Comperat E, Rozet F, Barret E, Drouin S, Vaessen C, Lucidarme O, Cussenot O, Boudghène F, Renard-Penna R. Transition zone and anterior stromal prostate cancers: Evaluation of discriminant location criteria using multiparametric fusion-guided biopsy. Diagn Interv Imaging 2018; 99:403-411. [DOI: 10.1016/j.diii.2018.01.006] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2017] [Revised: 01/03/2018] [Accepted: 01/18/2018] [Indexed: 01/12/2023]
|
27
|
Lotte R, Lafourcade A, Mozer P, Conort P, Barret E, Comperat E, Ezziane M, de Guibert PHJ, Tavolaro S, Belin L, Boudghene F, Lucidarme O, Renard-Penna R. Multiparametric MRI for Suspected Recurrent Prostate Cancer after HIFU:Is DCE still needed? Eur Radiol 2018; 28:3760-3769. [DOI: 10.1007/s00330-018-5352-z] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2017] [Accepted: 01/23/2018] [Indexed: 01/28/2023]
|
28
|
Luzurier A, Jouve De Guibert PH, Allera A, Feldman SF, Conort P, Simon JM, Mozer P, Compérat E, Boudghene F, Servois V, Lucidarme O, Granger B, Renard-Penna R. Dynamic contrast-enhanced imaging in localizing local recurrence of prostate cancer after radiotherapy: Limited added value for readers of varying level of experience. J Magn Reson Imaging 2018. [DOI: 10.1002/jmri.25991] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
Affiliation(s)
- Anna Luzurier
- Academic Department of Radiology, Hopital Pitié-Salpétrière, AP-HP; Sorbonne University Paris; France
| | | | - Alexandre Allera
- Academic Department of Radiology, Hopital Pitié-Salpétrière, AP-HP; Sorbonne University Paris; France
| | - Sarah F. Feldman
- Academic Departement of Statistic, Hopital Pitié-Salpétrière, AP-HP; Sorbonne University; France
| | - Pierre Conort
- Academic Department of Urology, Hopital Pitié-Salpétrière; AP-HP Sorbonne University; France
| | - Jean Marc Simon
- Academic Department of Radiotherapy, Hopital Pitié-Salpétrière, AP-HP; Sorbonne University; France
| | - Pierre Mozer
- Academic Department of Urology, Hopital Pitié-Salpétrière; AP-HP Sorbonne University; France
| | - Eva Compérat
- Academic Department of Pathology, Hopital Pitié-Salpétrière, AP-HP; Sorbonne University; France
| | - Franck Boudghene
- Academic Department of Radiology, Hopital Tenon, AP-HP; Sorbonne University; France
| | - Vincent Servois
- Academic department of Radiology; Curie Institute, Descartes Univ Paris 05; Paris France
| | - Olivier Lucidarme
- Academic Department of Radiology, Hopital Pitié-Salpétrière, AP-HP; Sorbonne University Paris; France
| | - Benjamin Granger
- Academic Departement of Statistic, Hopital Pitié-Salpétrière, AP-HP; Sorbonne University; France
| | - Raphaele Renard-Penna
- Academic Department of Radiology, Hopital Pitié-Salpétrière, AP-HP; Sorbonne University Paris; France
- Academic Department of Radiology, Hopital Tenon, AP-HP; Sorbonne University; France
- GRC-UPMC Oncotype-URO; Sorbonne University; Paris France
| |
Collapse
|
29
|
Guillot-Tantay C, Chartier-Kastler E, Mozer P, Bitker MO, Richard F, Ambrogi V, Denys P, Léon P, Phé V. [Male neurogenic stress urinary incontinence treated by artificial urinary sphincter AMS 800™ (Boston Scientific, Boston, USA): Very long-term results (>25 years)]. Prog Urol 2017; 28:39-47. [PMID: 29102375 DOI: 10.1016/j.purol.2017.09.012] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2017] [Revised: 08/03/2017] [Accepted: 09/26/2017] [Indexed: 11/17/2022]
Abstract
OBJECTIVE The aim of the study was to report the very long-term functional outcomes of artificial urinary sphincter (AUS) in male neurological patients. MATERIAL AND METHODS Male neurological patients diagnosed with stress urinary incontinence due to sphincter deficiency and undergoing AUS (AMS 800®) implantation between 1985 and 1992 were enrolled. Continence, defined by no pad/condom usage, explantation and revision rates were reported. RESULTS Fourteen patients with a median age of 27.3 years (IQR: 27.3-40.8) were included: four had a spinal cord injury and ten a spina bifida. Prior continence surgery was reported by 6 patients (42.9 %). Artificial urinary sphincter was implanted in a peribulbar (n=4) or periprostatic position (n=10). Median follow-up was 18.3 years (IQR: 10.1-20.3). At last follow-up, all patients were alive. Three native devices were still in place, eight were revised (four of them were secondarily explanted) and three were explanted due to erosion or infection. The 5-, 10-, 15-, 20-year explantation-free survival rates were respectively 85.7, 62.3, 52.0, 39.0 %. The 5-, 10-, 15-, 20-year revision-free survival rates were respectively 78.6, 42.9, 28.6, 7.1 %. At last follow-up, 50 % patients were continent. CONCLUSION In the very long run, AUS provided a 50 % continence rate in male neurological patients but the revision rates were important. LEVEL OF EVIDENCE 4.
Collapse
Affiliation(s)
- C Guillot-Tantay
- Service d'urologie et de transplantation rénale, hôpital universitaire La Pitié Salpêtrière, Assistance publique-Hôpitaux de Paris, faculté de médecine Pierre et Marie Curie, Sorbonne universités, université Paris 6, 47-83, boulevard de L'hôpital, 75013 Paris, France.
| | - E Chartier-Kastler
- Service d'urologie et de transplantation rénale, hôpital universitaire La Pitié Salpêtrière, Assistance publique-Hôpitaux de Paris, faculté de médecine Pierre et Marie Curie, Sorbonne universités, université Paris 6, 47-83, boulevard de L'hôpital, 75013 Paris, France
| | - P Mozer
- Service d'urologie et de transplantation rénale, hôpital universitaire La Pitié Salpêtrière, Assistance publique-Hôpitaux de Paris, faculté de médecine Pierre et Marie Curie, Sorbonne universités, université Paris 6, 47-83, boulevard de L'hôpital, 75013 Paris, France
| | - M-O Bitker
- Service d'urologie et de transplantation rénale, hôpital universitaire La Pitié Salpêtrière, Assistance publique-Hôpitaux de Paris, faculté de médecine Pierre et Marie Curie, Sorbonne universités, université Paris 6, 47-83, boulevard de L'hôpital, 75013 Paris, France
| | - F Richard
- Service d'urologie et de transplantation rénale, hôpital universitaire La Pitié Salpêtrière, Assistance publique-Hôpitaux de Paris, faculté de médecine Pierre et Marie Curie, Sorbonne universités, université Paris 6, 47-83, boulevard de L'hôpital, 75013 Paris, France
| | - V Ambrogi
- Service d'urologie et de transplantation rénale, hôpital universitaire La Pitié Salpêtrière, Assistance publique-Hôpitaux de Paris, faculté de médecine Pierre et Marie Curie, Sorbonne universités, université Paris 6, 47-83, boulevard de L'hôpital, 75013 Paris, France
| | - P Denys
- Service de médecine physique et réadaptation, hôpital Raymond-Poincaré, Assistance publique-Hôpitaux de Paris, UFR des sciences de la santé Simone Veil, université Versailles-Saint-Quentin-en-Yvelines, 104, boulevard Raymond-Poincaré, 92380 Garches, France
| | - P Léon
- Service d'urologie et de transplantation rénale, hôpital universitaire La Pitié Salpêtrière, Assistance publique-Hôpitaux de Paris, faculté de médecine Pierre et Marie Curie, Sorbonne universités, université Paris 6, 47-83, boulevard de L'hôpital, 75013 Paris, France
| | - V Phé
- Service d'urologie et de transplantation rénale, hôpital universitaire La Pitié Salpêtrière, Assistance publique-Hôpitaux de Paris, faculté de médecine Pierre et Marie Curie, Sorbonne universités, université Paris 6, 47-83, boulevard de L'hôpital, 75013 Paris, France
| |
Collapse
|
30
|
Rouvière O, Puech P, Penna RR, Claudon M, Roy C, Lechevallier FM, Petrucci MD, Rabilloud M, Pethelaz AS, Chambardel MD, Magaud L, Cros F, Delongchamps NB, Boutier R, Bratan F, Brunelle S, Camparo P, Colin P, Correas J, Cornelis F, Cornud F, Descotes J, Eschwege P, Fiard G, Fendler J, Habchi H, Hallouin P, Khairoune A, Lang H, Lebras Y, Malavaud B, Moldovan P, Mottet N, Mozer P, Nevoux P, Pagnoux G, Pasticier G, Portalez D, Potiron E, Timsit M, Villers A, Walz J, Colombel M, Ruffion A, Crouzet S, Lemaitre L, Grenier N. Valeur ajoutée de l’IRM de prostate avant première série de biopsies : étude MRI-FIRST. Prog Urol 2017. [DOI: 10.1016/j.purol.2017.07.062] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
31
|
Denormandie A, Chartier-Kastler E, Mozer P, Vaessen C, Ismael S, Deschênes-Rompré M, Phé V. Résultats fonctionnels à long terme du sphincter urinaire artificiel AMS 800, chez les patientes âgées de plus de 75 ans ayant une incontinence urinaire d’effort par insuffisance sphinctérienne. Prog Urol 2017. [DOI: 10.1016/j.purol.2017.07.160] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
32
|
Manach Q, Rouprêt M, Reboul-Marty J, Drouin SJ, Guillot-Tantay C, Matillon X, Parra J, Mozer P, Bitker MO, Lefèvre JH, Phé V. Hospital Readmissions After Urological Surgical Procedures in France: A Nationwide Cohort Study over 3 Years. Eur Urol Focus 2017; 4:621-627. [PMID: 28753813 DOI: 10.1016/j.euf.2017.06.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2017] [Revised: 05/11/2017] [Accepted: 06/02/2017] [Indexed: 10/19/2022]
Abstract
BACKGROUND Identifying the predictive factors for hospital readmission is required to target preventive measures. OBJECTIVE To assess the rate of surgical readmissions after a urological procedure and the risk factors associated with readmission. DESIGN, SETTING, AND PARTICIPANTS Data from all hospitalizations between January 2010 and November 2012 in France, regarding planned urological surgeries, were retrieved from the national medical database. To limit interactions between recent hospitalizations and surgical interventions, we selected only patients who were not hospitalized during the 12 mo preceding the urological procedure. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS Primary outcome was the rate of readmissions within 30 d after urological surgery. The following risk factors for readmission were assessed: sex, age, diagnosis-related group, length of stay of initial hospitalization, type of hospitalization (conventional or day surgery), hospital volume activity, hospital volume for day surgery, and hospital status. Logistic regression multivariate analysis was used to assess risk factors. RESULTS AND LIMITATIONS Overall, 419 787 patients were included among whom 77 241 patients (18.40%) were readmitted within the following 30 d. After multivariate analyses, male sex (odds ratio [OR]=1.84, confidence interval [CI] 95%: 1.81-1.88), high level of comorbidity (diagnosis-related group 3-4 vs 1-2: OR=2.14, CI 95%: 2.10-2.21), and initial management in a private hospital (private vs university hospital: OR=1.13, CI 95%: 1.11-1.16; private vs public general hospital: OR=1.21, CI 95%: 1.18-1.23) were associated with a higher risk of readmission within 30 d. CONCLUSIONS Reported readmission rate within 30 d after a planned a urological procedure was nearly 20%. PATIENT SUMMARY In this French national study, we investigated the readmission rate within 30 d after a planned urological procedure in a large French population and discovered it was nearly 20%.
Collapse
Affiliation(s)
- Quentin Manach
- Department of Urology, Pitié-Salpêtrière Academic Hospital, Assistance Publique-Hôpitaux de Paris, Pierre and Marie Curie Medical School, University Paris Sorbonne, Paris, France
| | - Morgan Rouprêt
- Department of Urology, Pitié-Salpêtrière Academic Hospital, Assistance Publique-Hôpitaux de Paris, Pierre and Marie Curie Medical School, University Paris Sorbonne, Paris, France.
| | - Jeanne Reboul-Marty
- Department of Medical Information, Marne la Vallée General Hospital, Jossigny, France
| | - Sarah J Drouin
- Department of Urology, Pitié-Salpêtrière Academic Hospital, Assistance Publique-Hôpitaux de Paris, Pierre and Marie Curie Medical School, University Paris Sorbonne, Paris, France
| | - Cyrille Guillot-Tantay
- Department of Urology, Pitié-Salpêtrière Academic Hospital, Assistance Publique-Hôpitaux de Paris, Pierre and Marie Curie Medical School, University Paris Sorbonne, Paris, France
| | - Xavier Matillon
- Department of Urology, Pitié-Salpêtrière Academic Hospital, Assistance Publique-Hôpitaux de Paris, Pierre and Marie Curie Medical School, University Paris Sorbonne, Paris, France
| | - Jérome Parra
- Department of Urology, Pitié-Salpêtrière Academic Hospital, Assistance Publique-Hôpitaux de Paris, Pierre and Marie Curie Medical School, University Paris Sorbonne, Paris, France
| | - Pierre Mozer
- Department of Urology, Pitié-Salpêtrière Academic Hospital, Assistance Publique-Hôpitaux de Paris, Pierre and Marie Curie Medical School, University Paris Sorbonne, Paris, France
| | - Marc-Oliver Bitker
- Department of Urology, Pitié-Salpêtrière Academic Hospital, Assistance Publique-Hôpitaux de Paris, Pierre and Marie Curie Medical School, University Paris Sorbonne, Paris, France
| | - Jérémie H Lefèvre
- Department of Digestive Surgery, Saint-Antoine Academic Hospital, Assistance Publique-Hôpitaux de Paris, Pierre and Marie Curie Medical School, University Paris Sorbonne, Paris, France
| | - Véronique Phé
- Department of Urology, Pitié-Salpêtrière Academic Hospital, Assistance Publique-Hôpitaux de Paris, Pierre and Marie Curie Medical School, University Paris Sorbonne, Paris, France
| |
Collapse
|
33
|
Renard-Penna R, Mozer P, Lunelli L, Cussenot O. [Role of prostate MRI, TRUS fusion biopsies and new markers in the diagnostic strategy of prostate cancer]. Presse Med 2017; 46:928-934. [PMID: 28502474 DOI: 10.1016/j.lpm.2017.03.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/28/2016] [Revised: 03/07/2017] [Accepted: 03/29/2017] [Indexed: 11/24/2022] Open
Abstract
Multiparametric MRI prostate (mp-MRI) is a powerful tool to locate lesions>0.5cm3 (below this threshold tumor volume, prostate cancers are classified as "insignificant"). The detection rate of the mp-MRI for significant cancers of small volume (0.5-1cm3) with a Gleason score≥7 is>85 %. The prostate mp-MRI optimizes the management of cancers classified as low risk of progression by providing aggressive criteria for misclassified lesions, which require an active treatment and enhance the clinicopathological criteria of indolence for subclinical lesions, which can justify of surveillance. MRI-mp coupled to the 3D ultrasound image fusion, optimizes the predictive value of biopsies and improves tumor staging, particularly when benign prostatic hyperplasia (>40cm3) is associated with clinical course. New tissue markers feasible on biopsies allow to define better the risk of progression of the small volume of cancer in order to reinforce the indications of surveillance or delayed curative treatment.
Collapse
Affiliation(s)
- Raphaële Renard-Penna
- AP-HP, UPMC, hôpitaux Tenon-Pitié-Salpétrière, services d'imagerie, rue de la Chine, boulevard de l'Hôpital, 75020 Paris, France.
| | - Pierre Mozer
- AP-HP, UPMC, hôpital de la Pitié-Salpétrière, service d'urologie, 75013 Paris, France
| | - Luca Lunelli
- AP-HP, UPMC, hôpital Tenon, service d'urologie, 75020 Paris, France
| | - Olivier Cussenot
- AP-HP, UPMC, hôpital Tenon, service d'urologie, 75020 Paris, France
| |
Collapse
|
34
|
Marin L, Ezziane M, Comperat E, Mozer P, Cancel-Tassin G, Coté JF, Racoceanu D, Boudghene F, Lucidarme O, Cussenot O, Renard Penna R. Comparison of semi-automated and manual methods to measure the volume of prostate cancer on magnetic resonance imaging. Diagn Interv Imaging 2017; 98:423-428. [DOI: 10.1016/j.diii.2017.02.004] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2017] [Revised: 02/20/2017] [Accepted: 02/23/2017] [Indexed: 11/25/2022]
|
35
|
Rouviere O, Puech P, Renard Penna R, Claudon M, Roy C, Mege Lechevallier F, Decaussin-Petrucci M, Rabilloud M, Schott Pethelaz A, Dubreuil Chambardel M, Magaud L, Cros F, Barry Delongchamps N, Boutier R, Bratan F, Brunelle S, Camparo P, Colin P, Correas J, Cornélis F, Cornud F, Descotes J, Eschwege P, Fiard G, Fendler J, Habchi H, Hallouin P, Khairoune A, Lang H, Lebras Y, Malavaud B, Moldovan P, Mottet N, Mozer P, Nevoux P, Pagnoux G, Pasticier G, Portalez D, Potiron E, Timsit MO, Villers A, Walz J, Colombel M, Ruffion A, Crouzet S, Lemaitre L, Grenier N. Added value of pre-biopsy prostate multiparametric MRI in biopsy-naïve patients: Preliminary results of the MRI-FIRST trial. ACTA ACUST UNITED AC 2017. [DOI: 10.1016/s1569-9056(17)30558-4] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
36
|
Cohen J, Andre C, Mozer P. [Targeted MRI prostate biopsies]. Prog Urol 2016; 26:854-859. [PMID: 27751816 DOI: 10.1016/j.purol.2016.09.069] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2016] [Accepted: 09/23/2016] [Indexed: 11/25/2022]
Abstract
Prostate cancer is the first cancer and the second cause of cancer death in men in France. It is now a major public health issue, particularly given the increase of life expectancy. If screening is based on blood PSA and clinical examination (DRE), diagnosis requires the histological analysis of prostate samples. In current clinical routine, these biopsies are performed by endorectal through ultrasound guidance. In most cases, the cancer is not visible in the ultrasound image and the latter is used to make a dozen samples (or core), distributed as best as possible in the prostate. To increase the accuracy and the contribution of these biopsies, the use of data acquired by the magnetic resonance imaging (MRI), as well as the fusion of ultrasound and MRI images, is a therapeutic undergoing validation, and today performed in many institutions with dedicated tools. The objective of this work is to present the practical arrangements for the implementation of these biopsies using the image fusion, and discuss the advantages and benefits.
Collapse
Affiliation(s)
- J Cohen
- Service d'urologie, hôpital de la Pitié-Salpêtrière, 47-83, boulevard de l'Hôpital, 75013 Paris, France.
| | - C Andre
- Service d'urologie, hôpital de la Pitié-Salpêtrière, 47-83, boulevard de l'Hôpital, 75013 Paris, France
| | - P Mozer
- Service d'urologie, hôpital de la Pitié-Salpêtrière, 47-83, boulevard de l'Hôpital, 75013 Paris, France
| |
Collapse
|
37
|
Delongchamps NB, Portalez D, Bruguière E, Rouvière O, Malavaud B, Mozer P, Fiard G, Cornud F. Are Magnetic Resonance Imaging-Transrectal Ultrasound Guided Targeted Biopsies Noninferior to Transrectal Ultrasound Guided Systematic Biopsies for the Detection of Prostate Cancer? J Urol 2016; 196:1069-75. [DOI: 10.1016/j.juro.2016.04.003] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/03/2016] [Indexed: 11/28/2022]
Affiliation(s)
- Nicolas Barry Delongchamps
- Department of Urology, Cochin University Hospital, Paris Descartes University, Paris, France
- Inserm Unit U1151, Paris Descartes University, Paris, France
| | | | | | - Olivier Rouvière
- Hospices Civils de Lyon, Department of Urinary and Vascular Radiology, Edouard Herriot Hospital and University Lyon 1, Lyon, France
| | | | - Pierre Mozer
- Hospices Civils de Lyon, Department of Urinary and Vascular Radiology, Edouard Herriot Hospital and University Lyon 1, Lyon, France
| | | | - François Cornud
- Department of Urology, Cochin University Hospital, Paris Descartes University, Paris, France
| | | |
Collapse
|
38
|
Phé V, Léon P, Granger B, Denys P, Bitker MO, Mozer P, Chartier-Kastler E. Stress urinary incontinence in female neurological patients: long-term functional outcomes after artificial urinary sphincter (AMS 800TM
) implantation. Neurourol Urodyn 2016; 36:764-769. [DOI: 10.1002/nau.23019] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2016] [Accepted: 03/30/2016] [Indexed: 11/10/2022]
Affiliation(s)
- Véronique Phé
- Department of Urology; Pitié-Salpêtrière Academic Hospital; Assistance Publique-Hôpitaux de Paris; Pierre and Marie Curie Medical School; Paris 6 University; Paris France
| | - Priscilla Léon
- Department of Urology; Pitié-Salpêtrière Academic Hospital; Assistance Publique-Hôpitaux de Paris; Pierre and Marie Curie Medical School; Paris 6 University; Paris France
| | - Benjamin Granger
- Department of Statistics; Pitié-Salpêtrière Academic Hospital; Assistance Publique-Hôpitaux de Paris; Pierre and Marie Curie Medical School; Paris 6 University; Paris France
| | - Pierre Denys
- Department of Physical Medicine and Rehabilitation; Raymond Poincaré Hospital; Assistance Publique-Hôpitaux de Paris; Paris France
| | - Marc-Olivier Bitker
- Department of Urology; Pitié-Salpêtrière Academic Hospital; Assistance Publique-Hôpitaux de Paris; Pierre and Marie Curie Medical School; Paris 6 University; Paris France
| | - Pierre Mozer
- Department of Urology; Pitié-Salpêtrière Academic Hospital; Assistance Publique-Hôpitaux de Paris; Pierre and Marie Curie Medical School; Paris 6 University; Paris France
| | - Emmanuel Chartier-Kastler
- Department of Urology; Pitié-Salpêtrière Academic Hospital; Assistance Publique-Hôpitaux de Paris; Pierre and Marie Curie Medical School; Paris 6 University; Paris France
| |
Collapse
|
39
|
Affiliation(s)
| | | | | | | | - Morgan Rouprêt
- Academic Department of Urology of La Pitié-Salpétrière, Assistance-Publique Hôpitaux de Paris, Faculté de Médecine Pierre et Marie Curie, University Paris 6; UPMC University Paris 06, GRC n°5, ONCOTYPE-URO, Paris, France
| |
Collapse
|
40
|
Peyronnet B, Wolff B, Drouin S, Mozer P, Renard-Penna R, Phé V, Chartier-Kastler E, Bitker M, Roupret M. Évaluation standardisée d’un protocole d’injections intralésionnelles de vérapamil pour maladie de Lapeyronie. Prog Urol 2015; 25:814. [DOI: 10.1016/j.purol.2015.08.197] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
41
|
Seisen T, Granger B, Colin P, Léon P, Utard G, Renard Penna R, Compérat E, Mozer P, Cussenot O, Shariat S, Rouprêt M. Revue systématique de la littérature et méta-analyse des facteurs de risque de récidive vésicale après néphro-uréterectomie totale pour le traitement d’une tumeur de la voie excrétrice urinaire supérieure. Prog Urol 2015; 25:805. [DOI: 10.1016/j.purol.2015.08.178] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
42
|
Peyronnet B, Kozal S, Seisen T, Comperat E, Vaessen C, Mozer P, Renard-penna R, Bitker M, Chartier-kastler E, Cussenot O, Rouprêt M, Drouin S. Facteurs histologiques associés au pronostic oncologique après prostatectomie robot-assistée. Prog Urol 2015; 25:793-4. [DOI: 10.1016/j.purol.2015.08.155] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
43
|
Seisen T, Rouprêt M, Cancel Tassin G, Léon P, Compérat E, Drouin S, Phé V, Renard Penna R, Mozer P, Cussenot O. Évaluation du risque de récidive vésicale par la recherche de la mutation FGFR3 sur l’ADN urinaire prélevé avant néphro-uréterectomie pour le traitement d’une tumeur de la voie excrétrice supérieure. Prog Urol 2015; 25:806. [DOI: 10.1016/j.purol.2015.08.180] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
44
|
Peyronnet B, Goujon A, Seisen T, Drouin S, Phé V, Mozer P, Chartier-kastler E, Bitker M, Rouprêt M. Anesthésie locale pour cystoscopie chez l’homme : étude prospective comparant le Xylocaine® gel et l’Instillagel®. Prog Urol 2015; 25:789. [DOI: 10.1016/j.purol.2015.08.146] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
45
|
Delongchamps NB, Portalez D, Bruguière E, Rouvière O, Malavaud B, Escourrou C, Fiard G, Pagnoux G, Descotes J, Roumiguié M, Mozer P, Renard-Penna R, Thoulouzan M, Hohn N, Cornud F. Trois biopsies ciblées par fusion d’image IRM – échographie sont-elles suffisantes pour diagnostiquer un cancer de la prostate en présence d’une image IRM prostatique suspecte et isolée ? Résultats de l’étude prospective multicentrique MURIELLE. Prog Urol 2015; 25:831. [DOI: 10.1016/j.purol.2015.08.229] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
46
|
Affiliation(s)
- P Léon
- Service d'urologie et andrologie, hôpital de la Pitié-Salpêtrière, Paris, France
| | - S Drouin
- Hôpital de la Pitié-Salpêtrière, Paris, France
| | - T Seisen
- Hôpital de la Pitié-Salpêtrière, Paris, France
| | | | - P Mozer
- Hôpital de la Pitié-Salpêtrière, Paris, France
| | - O Cussenot
- Hôpital de la Pitié-Salpêtrière, Paris, France
| | - M Bitker
- Hôpital de la Pitié-Salpêtrière, Paris, France
| | - M Rouprêt
- Hôpital de la Pitié-Salpêtrière, Paris, France
| |
Collapse
|
47
|
Renard-Penna R, Cancel-Tassin G, Comperat E, Varinot J, Léon P, Roupret M, Mozer P, Vaessen C, Lucidarme O, Bitker MO, Cussenot O. Multiparametric Magnetic Resonance Imaging Predicts Postoperative Pathology but Misses Aggressive Prostate Cancers as Assessed by Cell Cycle Progression Score. J Urol 2015; 194:1617-23. [PMID: 26272031 DOI: 10.1016/j.juro.2015.06.107] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/21/2015] [Indexed: 10/23/2022]
Abstract
PURPOSE We identified prognostic biomarkers in prostate cancer by a radiogenomics strategy that integrates gene expression using the cell cycle progression score and medical images. MATERIALS AND METHODS We obtained institutional review board approval and written informed consent from 106 men with prostate cancer, including 60% at low risk, who underwent multiparametric magnetic resonance imaging before radical prostatectomy was done and a cell cycle progression score was determined. The correlation between the results of multiparametric magnetic resonance imaging and Gleason grade or cell cycle progression score was assessed by logistic regression. RESULTS Patients with primary Gleason grade greater than 3 had a longer median maximal tumor diameter (13 vs 10 mm) and a lower median apparent diffusion coefficient (0.745 vs 0.88×10(-3) mm2 per second, each p=0.0001) than those with primary Gleason grade 3 or less. Maximal diameter 10 mm or greater (OR 4.9, 95% CI 1.7 to 14.0, p=0.0012) and apparent diffusion coefficient 0.80×10(-3) mm2 per second or less (OR 7.5, 95% CI 3.0 to 18.7, p<0.0001) were significantly associated with primary Gleason grade greater than 3. The combined measure of maximal diameter less than 10 mm and apparent diffusion coefficient greater than 0.80×10(-3) mm2 per second identified only index lesions harboring primary Gleason grade 3. However, 7 of those lesions showed a molecular pattern of high risk lethal prostate cancer (cell cycle progression score greater than 0). CONCLUSIONS Multiparametric magnetic resonance imaging is able to predict low and high risk Gleason scores in the tumor. However, the cell cycle progression score did not completely match the imaging result. These findings suggest that management of early stages prostate cancer could strongly benefit by performing magnetic resonance imaging targeted biopsy coupled with molecular analysis.
Collapse
Affiliation(s)
- Raphaële Renard-Penna
- Institut Universitaire de Cancérologie, ONCOTYPE-URO, GRC No. 5, Université Pierre et Marie Curie, Université Paris 06, Pitié-Salpêtrière Hospital, Paris, France; Department of Radiology, Pitié-Salpêtrière Hospital, Paris, France
| | - Géraldine Cancel-Tassin
- Institut Universitaire de Cancérologie, ONCOTYPE-URO, GRC No. 5, Université Pierre et Marie Curie, Université Paris 06, Pitié-Salpêtrière Hospital, Paris, France; Assistance Publique-Hôpitaux de Paris and Centre Recherche Pathologies Prostatique, Paris, France
| | - Eva Comperat
- Institut Universitaire de Cancérologie, ONCOTYPE-URO, GRC No. 5, Université Pierre et Marie Curie, Université Paris 06, Pitié-Salpêtrière Hospital, Paris, France; Department of Pathology, Pitié-Salpêtrière Hospital, Paris, France; Assistance Publique-Hôpitaux de Paris and Centre Recherche Pathologies Prostatique, Paris, France
| | - Justine Varinot
- Institut Universitaire de Cancérologie, ONCOTYPE-URO, GRC No. 5, Université Pierre et Marie Curie, Université Paris 06, Pitié-Salpêtrière Hospital, Paris, France; Department of Pathology, Pitié-Salpêtrière Hospital, Paris, France
| | - Priscilla Léon
- Institut Universitaire de Cancérologie, ONCOTYPE-URO, GRC No. 5, Université Pierre et Marie Curie, Université Paris 06, Pitié-Salpêtrière Hospital, Paris, France; Department of Urology, Pitié-Salpêtrière Hospital, Paris, France
| | - Morgan Roupret
- Institut Universitaire de Cancérologie, ONCOTYPE-URO, GRC No. 5, Université Pierre et Marie Curie, Université Paris 06, Pitié-Salpêtrière Hospital, Paris, France; Department of Urology, Pitié-Salpêtrière Hospital, Paris, France; Assistance Publique-Hôpitaux de Paris and Centre Recherche Pathologies Prostatique, Paris, France
| | - Pierre Mozer
- Institut Universitaire de Cancérologie, ONCOTYPE-URO, GRC No. 5, Université Pierre et Marie Curie, Université Paris 06, Pitié-Salpêtrière Hospital, Paris, France; Department of Urology, Pitié-Salpêtrière Hospital, Paris, France
| | - Christophe Vaessen
- Institut Universitaire de Cancérologie, ONCOTYPE-URO, GRC No. 5, Université Pierre et Marie Curie, Université Paris 06, Pitié-Salpêtrière Hospital, Paris, France; Department of Urology, Pitié-Salpêtrière Hospital, Paris, France
| | | | - Marc-Olivier Bitker
- Institut Universitaire de Cancérologie, ONCOTYPE-URO, GRC No. 5, Université Pierre et Marie Curie, Université Paris 06, Pitié-Salpêtrière Hospital, Paris, France; Department of Urology, Pitié-Salpêtrière Hospital, Paris, France
| | - Olivier Cussenot
- Institut Universitaire de Cancérologie, ONCOTYPE-URO, GRC No. 5, Université Pierre et Marie Curie, Université Paris 06, Pitié-Salpêtrière Hospital, Paris, France; Department of Urology, Pitié-Salpêtrière Hospital, Paris, France; Assistance Publique-Hôpitaux de Paris and Centre Recherche Pathologies Prostatique, Paris, France.
| |
Collapse
|
48
|
Gambachidze D, Phé V, Drouin SJ, Wolff B, Parra J, Mozer P, Renard-Penna R, Chartier-Kastler E, Rouprêt M. [Functional outcomes obtained after vesicoureteral reimplantation surgery in adults: A review]. Prog Urol 2015; 25:683-91. [PMID: 26184044 DOI: 10.1016/j.purol.2015.06.007] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2015] [Revised: 05/31/2015] [Accepted: 06/12/2015] [Indexed: 11/15/2022]
Abstract
OBJECTIVES Vesico-ureteral reimplantations (VUR) for adults are complex procedures, often practicing for distal ureteral lesions. Our goal was to synthesis the main indications for VUR, different techniques and their functional outcomes. MATERIAL AND METHODS A literature review in English by Medline, Embase and Google scholar was performed using the following keywords: ureter; laparoscopy; robotics, reimplantation; surgery; obstruction; morbidity; complications; psoas hitch; Boari flap; ureteroneocystostomy. RESULTS In more than half of the cases, aetiology was a iatrogenic ureteral lesion. When the ureteral defect was less than 2 cm, direct or non-refluxing VUR was the technique of choice. If defect was superior than 2 cm the Boari flap or vesicopsoas hitch were preferred. Several surgical approaches were feasible: open, laparoscopic only, robot assisted laparoscopic. Estimated blood loss, pain and mean hospital stay seemed better with conventional or robotic coelioscopy. Nevertheless, complications, pre-/post-operative renal function and mean operative time seemed similar. The most frequent major complication was the anastomotic urine leakage. CONCLUSIONS The VUR techniques are well codified now even if it's a rare procedure. Functional outcomes are satisfied according to literature and morbidity is more and more decreasing but the level of evidence of the studies is low.
Collapse
Affiliation(s)
- D Gambachidze
- Service d'urologie de l'hôpital Pitié-Salpêtrière, faculté de médecine Pierre-et-Marie-Curie, université Paris 6, AP-HP, 47-83, boulevard de l'Hôpital, 75013 Paris, France
| | - V Phé
- Service d'urologie de l'hôpital Pitié-Salpêtrière, faculté de médecine Pierre-et-Marie-Curie, université Paris 6, AP-HP, 47-83, boulevard de l'Hôpital, 75013 Paris, France
| | - S J Drouin
- Service d'urologie de l'hôpital Pitié-Salpêtrière, faculté de médecine Pierre-et-Marie-Curie, université Paris 6, AP-HP, 47-83, boulevard de l'Hôpital, 75013 Paris, France
| | - B Wolff
- Service d'urologie de l'hôpital Pitié-Salpêtrière, faculté de médecine Pierre-et-Marie-Curie, université Paris 6, AP-HP, 47-83, boulevard de l'Hôpital, 75013 Paris, France
| | - J Parra
- Service d'urologie de l'hôpital Pitié-Salpêtrière, faculté de médecine Pierre-et-Marie-Curie, université Paris 6, AP-HP, 47-83, boulevard de l'Hôpital, 75013 Paris, France
| | - P Mozer
- Service d'urologie de l'hôpital Pitié-Salpêtrière, faculté de médecine Pierre-et-Marie-Curie, université Paris 6, AP-HP, 47-83, boulevard de l'Hôpital, 75013 Paris, France
| | - R Renard-Penna
- Service d'urologie de l'hôpital Pitié-Salpêtrière, faculté de médecine Pierre-et-Marie-Curie, université Paris 6, AP-HP, 47-83, boulevard de l'Hôpital, 75013 Paris, France
| | - E Chartier-Kastler
- Service d'urologie de l'hôpital Pitié-Salpêtrière, faculté de médecine Pierre-et-Marie-Curie, université Paris 6, AP-HP, 47-83, boulevard de l'Hôpital, 75013 Paris, France
| | - M Rouprêt
- Service d'urologie de l'hôpital Pitié-Salpêtrière, faculté de médecine Pierre-et-Marie-Curie, université Paris 6, AP-HP, 47-83, boulevard de l'Hôpital, 75013 Paris, France.
| |
Collapse
|
49
|
Wolff B, Peyronnet B, Cattarino S, Mozer P, Renard-Penna R, Phé V, Bitker MO, Rouprêt M. Intralesional Injections for Early Peyronie Disease: Standardized Assessment and Analysis of Predictive Factors for Treatment Response. Urology 2015; 86:57-61. [DOI: 10.1016/j.urology.2015.03.010] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2015] [Revised: 02/19/2015] [Accepted: 03/13/2015] [Indexed: 11/15/2022]
|
50
|
Seisen T, Granger B, Colin P, Léon P, Utard G, Renard-Penna R, Compérat E, Mozer P, Cussenot O, Shariat SF, Rouprêt M. A Systematic Review and Meta-analysis of Clinicopathologic Factors Linked to Intravesical Recurrence After Radical Nephroureterectomy to Treat Upper Tract Urothelial Carcinoma. Eur Urol 2015; 67:1122-1133. [DOI: 10.1016/j.eururo.2014.11.035] [Citation(s) in RCA: 162] [Impact Index Per Article: 18.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2014] [Accepted: 11/18/2014] [Indexed: 12/26/2022]
|